{"gene":"STAT5B","run_date":"2026-04-28T20:42:08","timeline":{"discoveries":[{"year":1996,"finding":"STAT5A and STAT5B are activated by tyrosine phosphorylation in mammary tissue during lactation; upon phosphorylation, they form homo- and heterodimers that bind DNA and drive milk protein gene transcription. Phosphorylation correlates tightly with mammary gland differentiation.","method":"Isoform-specific antibodies, EMSA, supershift analysis, transgenic mice","journal":"Molecular endocrinology","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal methods (antibody-based detection, EMSA, in vivo transgenic model) in a single rigorous study","pmids":["8961260"],"is_preprint":false},{"year":1997,"finding":"GH induces tyrosine phosphorylation of both STAT5A and STAT5B via JAK2 kinase, requiring specific cytoplasmic regions of the GH receptor (C-terminal half; tyrosines 333/338); JAK2 is required for GH-dependent STAT5B tyrosine phosphorylation.","method":"Transient transfection in COS cells and CHO cells expressing truncated/mutated GH receptors, JAK2-deficient cell lines, Western blotting","journal":"Endocrinology","confidence":"High","confidence_rationale":"Tier 1/2 — reconstitution with receptor mutants + JAK2-deficient cells, multiple cell systems","pmids":["9231797"],"is_preprint":false},{"year":1998,"finding":"STAT5B, but not STAT5A, is essential for NK cell-mediated proliferation and cytolytic activity in response to IL-2 and IL-15; Stat5b-/- mice show diminished IL-2 receptor beta chain expression, reduced NK cell numbers and responsiveness.","method":"Stat5b knockout mice, proliferation assays, NK cytolytic activity assays","journal":"The Journal of experimental medicine","confidence":"High","confidence_rationale":"Tier 2 — clean KO with defined cellular phenotype, multiple functional readouts","pmids":["9841920"],"is_preprint":false},{"year":1998,"finding":"The CIS gene promoter contains paired STAT binding elements that bind STAT5 tetramers; STAT5A (but not STAT5B) can form tetrameric complexes on adjacent STAT sites, representing a biochemical distinction between the two isoforms. STAT5B binds as a homodimer with higher affinity than STAT5A.","method":"EMSA with nuclear extracts and purified recombinant proteins, transient transfection with STAT5A/B expression vectors, COS-7 cell model","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 1 — reconstitution with purified proteins + mutant analysis, replicated in cell extracts","pmids":["9742102"],"is_preprint":false},{"year":1998,"finding":"GM-CSF selectively activates JAK2, STAT3, and STAT5B (not STAT5A, STAT1, STAT2, STAT4, or STAT6) in human neutrophils; only the 92-kDa STAT5B isoform undergoes tyrosine phosphorylation and increased DNA binding in response to GM-CSF.","method":"Immunoprecipitation, Western blot, EMSA with isoform-specific antibodies","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 — reciprocal pulldown/IP with isoform-specific antibodies and EMSA, single lab but multiple orthogonal methods","pmids":["9422769"],"is_preprint":false},{"year":1998,"finding":"STAT5A and STAT5B bind to a single GAS-like element (ALS-GAS1) in the mouse acid-labile subunit (ALS) promoter in a GH-dependent manner, mediating GH-induced transcription of the ALS gene in hepatocytes.","method":"Promoter deletion analysis, luciferase reporter assays, EMSA with supershift using STAT5 antibodies, primary rat hepatocytes and H4-II-E hepatoma cells","journal":"Molecular endocrinology","confidence":"High","confidence_rationale":"Tier 1/2 — reporter assays with deletion mutants, EMSA supershift, primary cells","pmids":["9605930"],"is_preprint":false},{"year":1998,"finding":"GH and PRL activate STAT5B via JAK2 tyrosine phosphorylation in Leydig cells, inducing STAT5B nuclear translocation and DNA binding to GAS elements; the response is cell-type specific (immature but not adult primary Leydig cells respond to GH).","method":"Immunoprecipitation, Western blot, EMSA, primary rat Leydig cells and MA-10 mouse Leydig tumor cells","journal":"Endocrinology","confidence":"Medium","confidence_rationale":"Tier 2 — multiple biochemical methods, single lab","pmids":["9528973"],"is_preprint":false},{"year":1999,"finding":"STAT5b mediates GH-induced expression of SOCS-2 and SOCS-3 mRNA in liver but not in mammary gland, demonstrating tissue-specific STAT5b-dependent feedback regulation of GH signaling.","method":"STAT5b knockout mice, GH treatment, Northern blot/mRNA quantification","journal":"Molecular and cellular endocrinology","confidence":"High","confidence_rationale":"Tier 2 — clean KO with specific molecular readout, tissue specificity demonstrated","pmids":["10630411"],"is_preprint":false},{"year":1999,"finding":"Src kinase activates STAT5B by tyrosine phosphorylation leading to its nuclear translocation, but this occurs by a mechanism distinct from JAK-mediated cytokine activation: src-mediated STAT5B nuclear translocation does not depend on JAK2, is selective for STAT5B over STAT5A, and is mediated by C-terminal sequences of STAT5B. Src-activated STAT5B does not drive beta-casein promoter transcription despite nuclear translocation.","method":"Dominant-negative JAK2 overexpression, indirect immunofluorescence, co-transfection reporter assays","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal methods (immunofluorescence, dominant-negative, reporter assay) demonstrating mechanistic distinction","pmids":["10428824"],"is_preprint":false},{"year":1999,"finding":"Termination of GH pulse-induced STAT5b signaling requires synthesis of a labile protein factor (sensitive to cycloheximide), proteasome activity (sensitive to MG132), and phosphotyrosine phosphatase activity (sensitive to pervanadate); serine kinase inhibitor H7 sustains JAK2 signaling to STAT5b.","method":"CWSV-1 rat liver cell line, pharmacological inhibitors (cycloheximide, MG132, pervanadate, H7), GH pulse protocols","journal":"Molecular endocrinology","confidence":"High","confidence_rationale":"Tier 2 — multiple pharmacological dissection with defined mechanistic readouts, coherent model","pmids":["9892011"],"is_preprint":false},{"year":1999,"finding":"STAT5b is essential for GH pulse-dependent activation of male-specific liver P450 gene expression (CYP2D9) and body weight gain; STAT5b-deficient mice are GH pulse-resistant, demonstrating STAT5b is the key intracellular mediator of pulsatile GH effects in liver.","method":"STAT5b knockout mice, hypophysectomy + pulsatile GH replacement, liver gene expression analysis","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 — clean KO + hormone replacement experiment with specific molecular and physiological readouts","pmids":["10585399"],"is_preprint":false},{"year":1999,"finding":"Continuous (female-pattern) GH exposure down-regulates JAK2-STAT5b signaling in liver cells through enhanced dephosphorylation of both STAT5b and GHR-JAK2, with the JAK2 dephosphorylation leading to receptor internalization/degradation.","method":"CWSV-1 liver cell line, pharmacological inhibitors (pervanadate, proteasome inhibitors), continuous vs. pulsatile GH treatment protocols","journal":"Molecular endocrinology","confidence":"High","confidence_rationale":"Tier 2 — multiple pharmacological probes with mechanistic dissection, consistent model","pmids":["9973252"],"is_preprint":false},{"year":1999,"finding":"GH-activated STAT5b inhibits PPARalpha transcription by targeting the ligand-independent AF-1 transactivation domain of PPARalpha; a constitutively active STAT5b mutant does not inhibit PPARalpha, and SOCS-3 abolishes the inhibitory response.","method":"Transient transfection, luciferase reporter assays, GAL4-chimeric receptor constructs, constitutively active and dominant-negative STAT5b mutants","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1/2 — multiple domain-dissection reporter assays with mutants, mechanistic pathway placement","pmids":["10514468"],"is_preprint":false},{"year":2000,"finding":"STAT5a (but not STAT5b, STAT1–4, or STAT6) is potently activated by Flt3 ligand (FL) downstream of Flt3 receptor kinase without Jak activation; FL does not stimulate hematopoietic progenitor proliferation in Stat5a-/- mice but does in Stat5b-/- mice, demonstrating functional non-redundancy.","method":"Baf3/Flt3 stable cell line, EMSA, Stat5a-/- and Stat5b-/- mouse bone marrow progenitor assays","journal":"The Journal of experimental medicine","confidence":"High","confidence_rationale":"Tier 2 — epistasis via KO mice + in vitro assays, replicated across cell types","pmids":["10974037"],"is_preprint":false},{"year":2000,"finding":"PRL-inducible STAT5b inhibits NFκB-mediated signaling independently of STAT5b-DNA interactions but requiring the carboxyl terminus of STAT5b and nuclear translocation; the inhibition is reversed by overexpression of p300/CBP coactivator, suggesting competition for limiting coactivators.","method":"Transient transfection, luciferase reporter assays, dominant-negative STAT5b, p300/CBP overexpression","journal":"Molecular endocrinology","confidence":"High","confidence_rationale":"Tier 2 — multiple functional assays with domain/mutant dissection, coherent mechanistic model","pmids":["10628751"],"is_preprint":false},{"year":2001,"finding":"EGF activates STAT5b at three novel tyrosine sites (Tyr-725, Tyr-740, Tyr-743) in addition to Tyr-699; Tyr-699 is absolutely required for transcriptional activation while tyrosines 725, 740, 743 may negatively regulate transcription. EGF-induced STAT5b activation requires EGFR overexpression.","method":"Metabolic labeling, site-directed mutagenesis, luciferase reporter assays, stable EGFR-overexpressing HEK293 cells","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 — in vitro mutagenesis + metabolic labeling + reporter assays","pmids":["11751923"],"is_preprint":false},{"year":2001,"finding":"STAT5b serine phosphorylation at Ser730 contributes to GH-stimulated transcriptional activity in a promoter context-dependent manner; mutation of Ser730 to Ala reduces reporter activity ~50% at an isolated STAT5-binding site but causes ~2-fold higher activity at the intact beta-casein promoter.","method":"Mass spectrometry, site-directed mutagenesis, GH-stimulated luciferase reporter assays, serine kinase inhibitor H7","journal":"Molecular endocrinology","confidence":"High","confidence_rationale":"Tier 1 — mass spectrometry site identification + mutagenesis functional validation","pmids":["11731617"],"is_preprint":false},{"year":2002,"finding":"STAT5B mediates synergism between EGFR and c-Src: EGF-induced STAT5b tyrosine phosphorylation requires EGFR Tyr845 (a c-Src phosphorylation site), and dominant-negative STAT5b abolishes EGF-induced DNA synthesis, placing STAT5b downstream of the EGFR/c-Src axis.","method":"Tyrosine-to-phenylalanine receptor mutants, dominant-negative STAT5b, kinase-defective c-Src, luciferase reporter assays, DNA synthesis assays in human breast tumor cell lines","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 — multiple mutants + functional readouts, clear epistatic placement","pmids":["12429742"],"is_preprint":false},{"year":2002,"finding":"STAT5B shuttles between nucleus and cytoplasm via two distinct mechanisms: (1) a constitutive, cytokine-independent monomer import (requiring the coiled-coil domain, sensitive to leptomycin B indicating CRM1-dependent export), and (2) a cytokine-stimulated, tyrosine phosphorylation/dimerization-dependent import.","method":"Leptomycin B treatment, STAT5B Tyr699 mutant (dimerization-defective), deletion mutants, immunofluorescence in Ba/F3 cells","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 2 — multiple mutants + pharmacological dissection + localization imaging","pmids":["11971004"],"is_preprint":false},{"year":2003,"finding":"STAT5b is a key component of GH-stimulated IGF-I gene transcription in vivo: dominant-negative STAT5b completely prevents GH-stimulated IGF-I gene transcription in rat liver, while constitutively active STAT5b drives IGF-I expression in the absence of hormone.","method":"In vivo adenovirus-mediated gene transfer to pituitary-deficient rats, IGF-I mRNA quantification, constitutively active and dominant-negative STAT5b","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 — in vivo gene transfer with dominant-negative and constitutively active mutants, rigorous controls","pmids":["12682066"],"is_preprint":false},{"year":2003,"finding":"A Stat5b mutation (L327M) in NOD mice reduces DNA-binding affinity (Leu327 is the first residue in the STAT DNA-binding domain, conserved in all STATs), leading to decreased expression of Stat5b-regulated target genes IL-2Rβ and Pim1.","method":"Sequencing, homology modeling, DNA-protein binding assays, Western blotting","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 — structural modeling + binding assay + gene expression, single lab","pmids":["14701862"],"is_preprint":false},{"year":2003,"finding":"Constitutive activation of Stat5b contributes to squamous cell carcinogenesis in vivo; Stat5b antisense blockade inhibits tumor growth and abrogates Stat5 target gene expression in xenografts. EGFR links to Stat5b in vivo.","method":"Antisense oligonucleotide blockade in xenograft model, gene expression analysis","journal":"Cancer research","confidence":"Medium","confidence_rationale":"Tier 2 — in vivo loss-of-function with specific molecular readout, single lab","pmids":["14583472"],"is_preprint":false},{"year":2004,"finding":"In vivo, dominant-negative STAT5b completely inhibits GH-stimulated transcription of IGF-I, IGFBP-3, ALS, SOCS-1, SOCS-2, and CIS genes in rat liver, but has little effect on SOCS-3. Constitutively active STAT5b drives IGF-I, ALS, and IGFBP-3 without hormone but minimally affects SOCS family induction.","method":"In vivo adenovirus-mediated gene transfer to pituitary-deficient male rats, gene expression analysis, dominant-negative and constitutively active STAT5b","journal":"American journal of physiology. Endocrinology and metabolism","confidence":"High","confidence_rationale":"Tier 2 — in vivo gene transfer with gain/loss of function, multiple target gene readouts","pmids":["14761873"],"is_preprint":false},{"year":2004,"finding":"STAT5b and HNF4alpha exhibit bidirectional cross-talk in liver: HNF4alpha inhibits STAT5b transcriptional activity by blocking GH-stimulated JAK2 tyrosine phosphorylation (not STAT5b dephosphorylation), while STAT5b synergistically enhances HNF4alpha activity at the ApoCIII promoter.","method":"Transient transfection reporter assays in HepG2 cells, dominant-negative phosphatase 1B, pervanadate treatment, Western blot for JAK2 and STAT5b phosphorylation","journal":"The Biochemical journal","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal methods, mechanistic dissection at JAK2 level","pmids":["16584384"],"is_preprint":false},{"year":2005,"finding":"Stat5b binds two distinct GH response elements in the rat IGF-I locus in vivo in a GH-dependent manner (chromatin immunoprecipitation); each element contains one high-affinity and one lower-affinity Stat5b site; paired Stat5b sites in intron 2 are more than twice as effective as the 5'-distal element in driving transcription.","method":"Chromatin immunoprecipitation (ChIP), quantitative protein-DNA binding studies, biochemical reconstitution reporter assays","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1/2 — ChIP in vivo + quantitative binding + reconstitution reporter assays","pmids":["16339156"],"is_preprint":false},{"year":2006,"finding":"STAT5b is required for the in vivo accumulation and regulatory function of CD4+CD25high T regulatory cells; STAT5b(A630P) missense mutation in a patient leads to low FOXP3 expression, impaired Treg suppression, and reduced CD25 expression in response to IL-2.","method":"Patient study with homozygous STAT5b missense mutation, flow cytometry, functional Treg assays, in vitro IL-2 stimulation","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 2 — human mutation with multiple functional readouts; unique human model","pmids":["16920911"],"is_preprint":false},{"year":2006,"finding":"STAT5b mediates neurotensin-induced mitogenesis in prostate cancer cells via a c-Src/EGFR Tyr845/STAT5b pathway; mutant forms of EGFR (Y845F) or STAT5b, or catalytic inhibitors of EGFR, c-Src, and MMPs, abrogate NT-induced DNA synthesis.","method":"Site-directed mutant EGFR and STAT5b expression, selective kinase inhibitors, BrdU incorporation/cell counting, PC3 prostate cancer cells","journal":"Oncogene","confidence":"High","confidence_rationale":"Tier 2 — multiple mutants + inhibitors + functional proliferation assay, epistatic pathway established","pmids":["16862179"],"is_preprint":false},{"year":2006,"finding":"Thrombin activates STAT5B (not STAT5A) to induce Hsp27 and FGF-2 expression in vascular smooth muscle cells (VSMC), mediating VSMC growth and motility; STAT5B associates with STAT3 in response to thrombin.","method":"Dominant-negative adenoviral STAT5B/STAT5A constructs, siRNA against Hsp27, dominant-negative STAT3, co-immunoprecipitation, VSMC growth and motility assays","journal":"Circulation research","confidence":"High","confidence_rationale":"Tier 2 — isoform-specific dominant-negatives + RNAi + Co-IP, multiple functional readouts","pmids":["16527988"],"is_preprint":false},{"year":2006,"finding":"Nuclear EGFRvIII forms a complex with phosphorylated STAT5b, binds DNA, and cooperates with STAT5b to regulate the Bcl-XL promoter; STAT5b knockdown reduces Bcl-XL levels and sensitizes glioblastoma cells to cisplatin.","method":"Co-immunoprecipitation of nuclear EGFR-STAT5b, ChIP on Bcl-XL and Aurora A promoters, shRNA knockdown, cisplatin sensitivity assays","journal":"International journal of cancer","confidence":"High","confidence_rationale":"Tier 2 — nuclear Co-IP + ChIP + loss-of-function with functional consequence","pmids":["22729867"],"is_preprint":false},{"year":2006,"finding":"Glucocorticoids recruit STAT5B to the P4 promoter of bcl-X in lymphoid cells where it acts as a persistent repressor; inhibition of STAT5 activity converts glucocorticoid-induced repression to activation, associated with stable GR and RNA Pol II recruitment.","method":"ChIP, transient transfection reporter assays, STAT5 inhibition in S49 T cells and mouse thymocytes","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 — ChIP + reporter assays, but paper is retracted","pmids":["16959781"],"is_preprint":false},{"year":2010,"finding":"CPEB3 interacts with STAT5b in the nucleus and inhibits its transcriptional activity without disrupting STAT5b dimerization, DNA binding, or nuclear localization; EGFR is a direct transcriptional target of STAT5b in neurons, negatively regulated by CPEB3.","method":"Co-immunoprecipitation of CPEB3-STAT5b, STAT5b knockdown, reporter assays, NMDA receptor activation, neuronal CPEB3 nuclear accumulation","journal":"Nucleic acids research","confidence":"High","confidence_rationale":"Tier 2 — Co-IP + reporter assays + KD with target gene readout, multiple methods","pmids":["20639532"],"is_preprint":false},{"year":2010,"finding":"ZFP36L1 negatively regulates erythroid differentiation of CD34+ hematopoietic stem cells by directly binding the 3'-UTR of STAT5b mRNA and triggering its degradation, thereby down-regulating STAT5b protein and suppressing erythroid colony formation.","method":"ZFP36L1 overexpression, siRNA knockdown, 3'-UTR binding assay, erythroid colony formation assay","journal":"Molecular biology of the cell","confidence":"High","confidence_rationale":"Tier 2 — direct 3'-UTR binding + KD/OE with functional colony assay","pmids":["20702587"],"is_preprint":false},{"year":2010,"finding":"Stat5b has a predominant role over Stat5a in promoting prostate cancer cell viability and tumor growth; inhibition of Stat5a/b induces massive cancer cell death and reduces subcutaneous and orthotopic tumor growth in vivo, while Stat3 dominates metastasis promotion.","method":"siRNA knockdown, subcutaneous and orthotopic xenograft models, RNA-seq gene expression profiling","journal":"The American journal of pathology","confidence":"High","confidence_rationale":"Tier 2 — isoform-specific KD with in vivo tumor models and molecular profiling","pmids":["20167868"],"is_preprint":false},{"year":2012,"finding":"STAT5b Ser-193 is a novel cytokine-induced phosphorylation site identified by mass spectrometry; it is phosphorylated rapidly in the cytoplasm prior to nuclear translocation, requires mTOR kinase and PP2A dephosphorylates it, and is required for maximal STAT5b transcriptional activity.","method":"Mass spectrometry, phospho-specific antibodies, mTOR and PP2A inhibitors, site-directed mutagenesis, EMSA, reporter assays, HEK293 reconstitution","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 — mass spectrometry site ID + mutagenesis + kinase/phosphatase inhibitor dissection + reporter assay","pmids":["22442148"],"is_preprint":false},{"year":2013,"finding":"Somatic STAT5B mutations (Y665F, N642H) in the SH2 domain increase STAT5 tyrosine phosphorylation and transcriptional activity in LGL leukemia cells, representing the first somatic STAT5 gain-of-function mutations discovered in human cancer.","method":"Exome and transcriptome sequencing, targeted amplicon sequencing, transfection of mutant constructs with phosphorylation and transcriptional activity assays","journal":"Blood","confidence":"High","confidence_rationale":"Tier 2 — sequencing + functional validation of mutant constructs with molecular readouts","pmids":["23596048"],"is_preprint":false},{"year":2015,"finding":"STAT5B N642H mutation in the SH2 domain causes markedly increased binding affinity of phosphotyrosine-Y699 with the mutant histidine (surface plasmon resonance), prolonged persistence of phospho-STAT5B, and increased binding to target sites, conferring growth advantage to NK and γδ-T cells.","method":"Molecular modelling, surface plasmon resonance, next-generation sequencing, transduction of cell lines and primary NK cells, JAK1/2 inhibitor treatment","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 1/2 — biophysical SPR measurement + structural modeling + functional cell assays","pmids":["25586472"],"is_preprint":false},{"year":2015,"finding":"The STAT5b SH2 domain can be selectively inhibited over STAT5a (>50-fold) by the natural product-inspired small molecule Stafib-1 (Ki=44 nM); binding site validated by point mutant functional analysis.","method":"In vitro SH2 domain binding assay, point mutant analysis, tumor cell phosphorylation inhibition","journal":"Angewandte Chemie","confidence":"High","confidence_rationale":"Tier 1/2 — biochemical binding assay with mutants + cellular validation","pmids":["25702814"],"is_preprint":false},{"year":2017,"finding":"Cryptochromes regulate IGF-1 production by controlling JAK2-dependent STAT5B phosphorylation at Y699 in liver and skeletal muscle; CRY deficiency reduces STAT5B Y699 phosphorylation without reducing JAK2 phosphorylation, placing CRY function downstream of JAK2 in the GH-STAT5B-IGF-1 axis.","method":"Cry-deficient mice, phospho-specific antibodies, IGF-1 ELISA, qPCR","journal":"Molecular biology of the cell","confidence":"High","confidence_rationale":"Tier 2 — genetic KO with phosphorylation-level epistasis and multiple readouts","pmids":["28100634"],"is_preprint":false},{"year":2017,"finding":"Musculin (MSC) expressed in human Th17 cells in an RORγt-dependent manner upregulates PPP2R2B (PP2A regulatory subunit), which dephosphorylates STAT5B Ser-193, thereby reducing STAT5B transcriptional activity and IL-2 responsiveness in Th17 cells.","method":"Th17 cell expression analysis, PP2A inhibitor experiments, Ser-193 phosphorylation assay, gene reporter assays","journal":"European journal of immunology","confidence":"High","confidence_rationale":"Tier 2 — mechanistic pathway linking MSC→PP2A→pSer193-STAT5B→reduced transcription, multiple methods","pmids":["28612433"],"is_preprint":false},{"year":2018,"finding":"Dominant-negative STAT5B missense mutants are tyrosine phosphorylated but fail to localize to the nucleus or fail to bind canonical DNA response elements; each retains the ability to dimerize with wild-type STAT5B, thereby disrupting wild-type STAT5B transcriptional function through dominant-negative mechanism.","method":"Patient germline mutations, nuclear localization assays, EMSA for DNA binding, dimerization assays, transcriptional reporter assays","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 2 — multiple mutants with distinct mechanistic defects identified by orthogonal assays in patient-derived and transfected cells","pmids":["29844444"],"is_preprint":false},{"year":2018,"finding":"cAMP-PKA signaling upregulates STAT5B in human trophoblast cells, and STAT5B knockdown decreases FSK-induced cell fusion and expression of syncytialization markers (CGB, syncytin2, GCM1, OVOL1), establishing STAT5B as a positive regulator of trophoblast syncytialization.","method":"siRNA knockdown of STAT5B, microarray, qPCR, syncytialization functional assays in BeWo cells","journal":"Journal of cellular biochemistry","confidence":"Medium","confidence_rationale":"Tier 3 — single KD approach with functional readout, single lab","pmids":["29377304"],"is_preprint":false},{"year":2019,"finding":"Crystal structures of human STAT5B and STAT5B-N642H reveal alternative SH2 domain conformations; biophysical data suggests the N642H mutant can adopt hyper-activated and hyper-inactivated states with resistance to dephosphorylation; MD simulations support sustained interchain cross-domain interactions in the N642H anti-parallel dimer.","method":"X-ray crystallography (human STAT5B and N642H crystal structures), biophysical assays, molecular dynamics simulations, transgenic mouse model, in vivo syngeneic transplant model","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 1 — crystal structure + MD simulation + biophysical data + in vivo functional validation","pmids":["31175292"],"is_preprint":false},{"year":2019,"finding":"STAT5B (not STAT5A) is the major STAT5 isoform driving BCR/ABL-induced leukemogenesis; STAT5B-deficient BCR/ABL+ cells show enhanced IFN-α and IFN-γ signatures, and IFN pathway inhibition rescues BCR/ABL+ colony formation of Stat5b-/- cells, demonstrating that STAT5B enables transformation by suppressing IFN responses.","method":"STAT5A/B-deficient BCR/ABL-expressing cells, RNA-seq, colony formation assays, IFN inhibition rescue experiments","journal":"Leukemia","confidence":"High","confidence_rationale":"Tier 2 — genetic KO + epistasis rescue + RNA-seq pathway analysis","pmids":["30679796"],"is_preprint":false},{"year":2022,"finding":"STAT5B restrains human B-cell differentiation into plasmablasts via IL-21 signaling; STAT5B deletion in B cells diminishes IL-21-mediated SOCS3 induction and BCL6 repression, leading to enhanced plasmablast generation and class switching.","method":"CRISPR-mediated STAT5B deletion in B-cell lines, primary lymphocytes from STAT5B-null patients, RNA-seq, phospho-flow cytometry, in vitro differentiation assays","journal":"The Journal of allergy and clinical immunology","confidence":"High","confidence_rationale":"Tier 2 — CRISPR KO + human patient cells + multiple molecular and functional readouts","pmids":["35469842"],"is_preprint":false}],"current_model":"STAT5B is a latent transcription factor activated by JAK2-dependent tyrosine phosphorylation (at Y699) downstream of cytokine receptors (GH, IL-2, IL-15, prolactin, GM-CSF, EPO) and non-receptor tyrosine kinases (c-Src, BCR/ABL, EGFRvIII); upon phosphorylation it dimerizes, translocates to the nucleus (also constitutively shuttles as a monomer via a CRM1-dependent mechanism), binds GAS-element-containing promoters to drive target gene transcription (IGF-I, ALS, IGFBP-3, SOCS-2/3, CIS, Bcl-XL, cyclin D1), and is terminated by phosphotyrosine phosphatases and proteasome-dependent degradation; its transcriptional activity is further modulated by serine phosphorylation (Ser730, Ser193), bidirectional inhibitory cross-talk with PPARα/γ and HNF4α, inhibition of NFκB signaling by competition for p300/CBP, interaction with co-regulators such as CPEB3 and glucocorticoid receptor, and negative feedback through SOCS proteins; gain-of-function mutations (especially N642H in the SH2 domain) increase phospho-STAT5B persistence by enhancing pY-SH2 binding affinity and conferring dephosphorylation resistance, driving aggressive T/NK-cell lymphomas."},"narrative":{"teleology":[{"year":1996,"claim":"Establishing that STAT5A and STAT5B are phosphorylation-activated transcription factors that dimerize and bind DNA to drive differentiation-associated gene expression revealed STAT5B as a signal-dependent latent transcription factor.","evidence":"Isoform-specific antibodies, EMSA with supershift, transgenic mouse mammary tissue","pmids":["8961260"],"confidence":"High","gaps":["Upstream kinase not yet identified","Individual contributions of STAT5A vs STAT5B not separated"]},{"year":1997,"claim":"Demonstrating that JAK2 is required for GH-induced STAT5B tyrosine phosphorylation and that specific GH receptor cytoplasmic tyrosines are needed placed STAT5B directly downstream of the JAK2-GHR complex.","evidence":"GH receptor truncation/mutation constructs in COS and CHO cells, JAK2-deficient cell lines","pmids":["9231797"],"confidence":"High","gaps":["Precise STAT5B recruitment mechanism to receptor not defined","Whether JAK2 directly phosphorylates Y699 or acts indirectly not resolved"]},{"year":1998,"claim":"Knockout studies and isoform-specific biochemistry revealed non-redundant functions: STAT5B (not STAT5A) is essential for NK cell proliferation/cytolysis downstream of IL-2/IL-15, GM-CSF selectively activates STAT5B in neutrophils, and STAT5B binds GAS elements as homodimers with higher affinity than STAT5A, while only STAT5A forms tetramers.","evidence":"Stat5b−/− mice with NK cell assays; isoform-specific IP/EMSA in neutrophils; purified recombinant protein EMSA and COS-7 transfection","pmids":["9841920","9422769","9742102","9605930"],"confidence":"High","gaps":["Structural basis of isoform-specific receptor recruitment unknown","Why STAT5B but not STAT5A is selectively activated in some cell types not mechanistically explained"]},{"year":1999,"claim":"A suite of discoveries established how STAT5B signaling is terminated (phosphatases, proteasome, labile inhibitory factor), how continuous vs pulsatile GH patterns produce different STAT5B activation states (explaining sexual dimorphism of liver gene expression), and how c-Src activates STAT5B via a JAK2-independent mechanism that is functionally distinct from cytokine-driven activation.","evidence":"Pharmacological dissection (MG132, pervanadate, cycloheximide, H7) in liver cells; Stat5b−/− mice with pulsatile GH replacement; dominant-negative JAK2 + immunofluorescence in transfected cells","pmids":["9892011","9973252","10585399","10428824","10630411"],"confidence":"High","gaps":["Identity of the labile protein factor required for signaling termination not determined","How Src-phosphorylated nuclear STAT5B fails to activate certain promoters remains unclear"]},{"year":2000,"claim":"Showing that STAT5B inhibits NF-κB signaling by competing for limiting p300/CBP coactivators revealed a transcription-independent function of activated STAT5B as a coactivator titrator, broadening its role beyond direct DNA binding.","evidence":"PRL-stimulated reporter assays with p300/CBP rescue, dominant-negative STAT5B, C-terminal deletion mutants","pmids":["10628751"],"confidence":"High","gaps":["Whether this occurs on endogenous NF-κB target genes in vivo not shown","Stoichiometry of STAT5B vs NF-κB competition for p300/CBP not quantified"]},{"year":2001,"claim":"Identification of Tyr-699 as the essential activating phosphosite plus three additional EGF-induced tyrosine sites (725, 740, 743) that negatively modulate transcription, and of Ser730 as a promoter-context-dependent modulator of transcriptional output, revealed multi-site phosphorylation-based regulation of STAT5B activity.","evidence":"Mass spectrometry + site-directed mutagenesis + reporter assays in EGFR-overexpressing HEK293 and GH-stimulated cells","pmids":["11751923","11731617"],"confidence":"High","gaps":["Kinase(s) responsible for Y725/740/743 phosphorylation not identified","In vivo relevance of Ser730 phosphorylation not tested"]},{"year":2002,"claim":"Discovery that STAT5B constitutively shuttles between nucleus and cytoplasm via a CRM1-dependent export pathway independently of cytokine stimulation, with a separate dimerization-dependent import mechanism upon activation, defined two distinct nuclear trafficking modes.","evidence":"Leptomycin B treatment, Y699 dimerization-defective mutant, coiled-coil domain deletions, immunofluorescence in Ba/F3 cells","pmids":["11971004"],"confidence":"High","gaps":["Nuclear import receptor for the monomer pathway not identified","Functional consequence of constitutive shuttling remains unclear"]},{"year":2003,"claim":"In vivo adenoviral gene transfer demonstrated that STAT5B is necessary and sufficient for GH-stimulated transcription of the IGF-I, ALS, IGFBP-3, SOCS-1, SOCS-2, and CIS genes in liver, establishing it as the master mediator of the hepatic GH-IGF axis.","evidence":"Dominant-negative and constitutively active STAT5B adenoviral vectors delivered to pituitary-deficient rats, with multi-gene expression readouts","pmids":["12682066","14761873"],"confidence":"High","gaps":["Chromatin-level mechanism of target gene selectivity not determined at this stage","Contribution of STAT5A to residual GH responses in liver not fully excluded"]},{"year":2005,"claim":"ChIP identification of two distinct STAT5B-occupied GH response elements in the IGF-I locus, each with paired high- and low-affinity sites, provided the first chromatin-level map of STAT5B binding at a key physiological target.","evidence":"Chromatin immunoprecipitation in rat liver, quantitative binding studies, reconstitution reporter assays","pmids":["16339156"],"confidence":"High","gaps":["Whether STAT5B tetramers vs dimers occupy these paired sites in vivo not resolved","Enhancer-promoter looping mechanism not addressed"]},{"year":2006,"claim":"Multiple studies expanded STAT5B's biological reach: it is required for CD4+CD25high Treg cell accumulation and FOXP3 expression (shown by a human A630P loss-of-function mutation), cooperates with nuclear EGFRvIII on the Bcl-XL promoter in glioblastoma, and mediates thrombin-induced VSMC growth via STAT3 co-association.","evidence":"Patient germline mutation with Treg functional assays; nuclear Co-IP + ChIP + shRNA in glioblastoma cells; dominant-negative STAT5B adenovirus + Co-IP in VSMC","pmids":["16920911","22729867","16527988"],"confidence":"High","gaps":["Whether STAT5B directly binds FOXP3 regulatory elements not tested","How EGFRvIII translocates to the nucleus to partner with STAT5B not explained"]},{"year":2012,"claim":"Identification of Ser-193 as an mTOR-dependent, PP2A-reversed cytoplasmic phosphorylation event required for maximal STAT5B transcriptional activity revealed an additional signaling input that modulates STAT5B before nuclear entry.","evidence":"Mass spectrometry, phospho-specific antibodies, mTOR/PP2A inhibitors, site-directed mutagenesis, HEK293 reconstitution","pmids":["22442148"],"confidence":"High","gaps":["Whether mTOR directly phosphorylates Ser-193 or acts through an intermediate kinase not determined","Interplay between Ser-193 and Ser-730 phosphorylation not studied"]},{"year":2013,"claim":"Discovery of somatic gain-of-function STAT5B mutations (N642H, Y665F) in the SH2 domain in LGL leukemia established STAT5B as a directly mutated oncogene in human cancer.","evidence":"Exome/transcriptome sequencing of LGL leukemia, targeted amplicon sequencing, transfection of mutant constructs with phosphorylation and transcriptional activity assays","pmids":["23596048"],"confidence":"High","gaps":["Mechanism by which N642H increases phosphorylation persistence not yet biophysically explained","Frequency and spectrum of STAT5B mutations across other lymphoid malignancies not yet surveyed"]},{"year":2015,"claim":"Biophysical characterization showed that N642H creates enhanced pY699-SH2 binding affinity (SPR) and dephosphorylation resistance, explaining the prolonged phospho-STAT5B persistence observed in N642H-driven lymphomas and providing a structural rationale for oncogenicity.","evidence":"Surface plasmon resonance, molecular modelling, transduction of NK and γδ-T cells, JAK1/2 inhibitor treatment","pmids":["25586472"],"confidence":"High","gaps":["Crystal structure of mutant not yet available at this time","Whether dephosphorylation resistance reflects altered phosphatase binding or intrinsic dimer stability not distinguished"]},{"year":2018,"claim":"Functional dissection of dominant-negative STAT5B germline mutations showed that distinct mutants fail at different steps (nuclear localization vs DNA binding) yet all retain dimerization capacity, establishing the molecular logic of dominant-negative STAT5B disease.","evidence":"Patient germline mutations, nuclear localization assays, EMSA, dimerization assays, reporter assays","pmids":["29844444"],"confidence":"High","gaps":["Whether heterodimers with STAT5A are also formed and functionally impaired not tested","In vivo rescue of dominant-negative phenotype not demonstrated"]},{"year":2019,"claim":"Crystal structures of wild-type STAT5B and the N642H mutant revealed alternative SH2 domain conformations and dephosphorylation resistance at the structural level, while functional studies showed STAT5B (not STAT5A) is the major driver of BCR/ABL leukemogenesis by suppressing interferon responses.","evidence":"X-ray crystallography + MD simulations + transgenic/syngeneic mouse models; Stat5b−/− BCR/ABL+ cells + RNA-seq + IFN inhibition rescue","pmids":["31175292","30679796"],"confidence":"High","gaps":["Full-length phosphorylated dimer structure not yet solved","How STAT5B suppresses IFN pathway transcription at the chromatin level not defined"]},{"year":2022,"claim":"CRISPR deletion and patient-derived cells showed STAT5B restrains B-cell differentiation into plasmablasts via IL-21-mediated SOCS3 induction and BCL6 repression, expanding STAT5B's non-redundant immune roles to humoral immunity.","evidence":"CRISPR KO in B-cell lines, primary cells from STAT5B-null patients, RNA-seq, phospho-flow, in vitro differentiation","pmids":["35469842"],"confidence":"High","gaps":["Direct STAT5B binding at SOCS3 and BCL6 loci in B cells not shown by ChIP","Whether enhanced plasmablast formation contributes to autoimmunity in STAT5B-deficient patients not established"]},{"year":null,"claim":"Key unresolved questions include: the full-length phosphorylated STAT5B dimer structure, the identity of nuclear import receptors for monomeric STAT5B, the chromatin-level basis for promoter selectivity among STAT5B target genes, and the therapeutic window for selective STAT5B inhibition in N642H-driven lymphomas.","evidence":"","pmids":[],"confidence":"Medium","gaps":["Full-length activated dimer crystal structure not available","Nuclear import receptor for constitutive monomer shuttling not identified","Genome-wide chromatin occupancy comparison of STAT5B vs STAT5A not performed in most cell types"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0003677","term_label":"DNA binding","supporting_discovery_ids":[0,3,5,24]},{"term_id":"GO:0140110","term_label":"transcription regulator activity","supporting_discovery_ids":[0,5,19,22,28,43]}],"localization":[{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[18,33]},{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[8,18,28,30]}],"pathway":[{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[1,4,6,9,11,15,17,37]},{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[0,5,19,22,24,28,43]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[2,25,42,43]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[34,35,41,42]}],"complexes":["STAT5B homodimer","STAT5A/STAT5B heterodimer","EGFRvIII-STAT5B nuclear complex"],"partners":["JAK2","STAT5A","STAT3","GHR","CPEB3","EGFRVIII","SRC","BCR-ABL"],"other_free_text":[]},"mechanistic_narrative":"STAT5B is a latent cytoplasmic transcription factor that is activated by JAK2-dependent tyrosine phosphorylation at Y699 downstream of cytokine receptors for growth hormone, prolactin, IL-2, IL-15, GM-CSF, and EPO, as well as by non-receptor tyrosine kinases including c-Src and BCR/ABL; upon phosphorylation it dimerizes, translocates to the nucleus, and binds GAS elements to drive transcription of target genes including IGF-I, ALS, IGFBP-3, Bcl-XL, SOCS-2, SOCS-3, and CIS [PMID:9231797, PMID:12682066, PMID:14761873, PMID:10428824]. Signal termination involves phosphotyrosine phosphatases and proteasome-dependent degradation, while transcriptional output is further tuned by serine phosphorylation at Ser730 and Ser193 (the latter regulated by mTOR and PP2A), bidirectional cross-talk with PPARα and HNF4α, competition with NF-κB for p300/CBP coactivators, and negative feedback through SOCS proteins [PMID:9892011, PMID:11731617, PMID:22442148, PMID:10514468, PMID:10628751]. STAT5B has non-redundant roles in NK cell cytolytic function, CD4+CD25high regulatory T cell homeostasis, GH-dependent sexually dimorphic liver gene expression, and restraint of B-cell plasmablast differentiation; germline loss-of-function mutations cause growth hormone insensitivity and immune dysregulation, while dominant-negative missense mutants dimerize with wild-type STAT5B to block its nuclear localization or DNA binding [PMID:9841920, PMID:16920911, PMID:10585399, PMID:35469842, PMID:29844444]. Somatic gain-of-function SH2-domain mutations, particularly N642H, increase pY699-SH2 binding affinity and confer dephosphorylation resistance, driving constitutive STAT5B activation in aggressive T-cell and NK-cell lymphomas [PMID:23596048, PMID:25586472, PMID:31175292]."},"prefetch_data":{"uniprot":{"accession":"P51692","full_name":"Signal transducer and activator of transcription 5B","aliases":[],"length_aa":787,"mass_kda":89.9,"function":"Carries out a dual function: signal transduction and activation of transcription (PubMed:29844444). Mediates cellular responses to the cytokine KITLG/SCF and other growth factors. Binds to the GAS element and activates PRL-induced transcription. Positively regulates hematopoietic/erythroid differentiation","subcellular_location":"Cytoplasm; Nucleus","url":"https://www.uniprot.org/uniprotkb/P51692/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/STAT5B","classification":"Not Classified","n_dependent_lines":34,"n_total_lines":1208,"dependency_fraction":0.028145695364238412},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/STAT5B","total_profiled":1310},"omim":[{"mim_id":"618985","title":"GROWTH HORMONE INSENSITIVITY SYNDROME WITH IMMUNE DYSREGULATION 2, AUTOSOMAL DOMINANT; GHISID2","url":"https://www.omim.org/entry/618985"},{"mim_id":"618796","title":"SAC3 DOMAIN-CONTAINING PROTEIN 1; SAC3D1","url":"https://www.omim.org/entry/618796"},{"mim_id":"612376","title":"ACUTE PROMYELOCYTIC LEUKEMIA; APL","url":"https://www.omim.org/entry/612376"},{"mim_id":"609888","title":"LEPROSY, SUSCEPTIBILITY TO, 1; LPRS1","url":"https://www.omim.org/entry/609888"},{"mim_id":"608937","title":"SH2B ADAPTOR PROTEIN 1; SH2B1","url":"https://www.omim.org/entry/608937"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Cytosol","reliability":"Supported"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/STAT5B"},"hgnc":{"alias_symbol":[],"prev_symbol":[]},"alphafold":{"accession":"P51692","domains":[{"cath_id":"1.10.532.10","chopping":"4-127","consensus_level":"high","plddt":88.4885,"start":4,"end":127},{"cath_id":"1.20.1050.20","chopping":"155-328","consensus_level":"high","plddt":94.1575,"start":155,"end":328},{"cath_id":"2.60.40.630","chopping":"338-472","consensus_level":"high","plddt":90.834,"start":338,"end":472},{"cath_id":"3.30.505.10","chopping":"503-683","consensus_level":"medium","plddt":93.6426,"start":503,"end":683}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P51692","model_url":"https://alphafold.ebi.ac.uk/files/AF-P51692-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P51692-F1-predicted_aligned_error_v6.png","plddt_mean":85.19},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=STAT5B","jax_strain_url":"https://www.jax.org/strain/search?query=STAT5B"},"sequence":{"accession":"P51692","fasta_url":"https://rest.uniprot.org/uniprotkb/P51692.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P51692/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P51692"}},"corpus_meta":[{"pmid":"25586472","id":"PMC_25586472","title":"Activating mutations of STAT5B and STAT3 in lymphomas derived from γδ-T or NK cells.","date":"2015","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/25586472","citation_count":327,"is_preprint":false},{"pmid":"18347089","id":"PMC_18347089","title":"Interpretation of cytokine signaling through the transcription factors STAT5A and STAT5B.","date":"2008","source":"Genes & development","url":"https://pubmed.ncbi.nlm.nih.gov/18347089","citation_count":284,"is_preprint":false},{"pmid":"10851055","id":"PMC_10851055","title":"The role of Stat5a and Stat5b in signaling by IL-2 family cytokines.","date":"2000","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/10851055","citation_count":280,"is_preprint":false},{"pmid":"9841920","id":"PMC_9841920","title":"Stat5b is essential for natural killer cell-mediated proliferation and cytolytic activity.","date":"1998","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/9841920","citation_count":256,"is_preprint":false},{"pmid":"23596048","id":"PMC_23596048","title":"Discovery of somatic STAT5b mutations in large granular lymphocytic leukemia.","date":"2013","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/23596048","citation_count":247,"is_preprint":false},{"pmid":"8961260","id":"PMC_8961260","title":"Activation of Stat5a and Stat5b by tyrosine phosphorylation is tightly linked to mammary gland differentiation.","date":"1996","source":"Molecular endocrinology (Baltimore, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/8961260","citation_count":214,"is_preprint":false},{"pmid":"10743504","id":"PMC_10743504","title":"Stat5a and Stat5b: fraternal twins of signal transduction and transcriptional activation.","date":"1999","source":"Cytokine & growth factor reviews","url":"https://pubmed.ncbi.nlm.nih.gov/10743504","citation_count":198,"is_preprint":false},{"pmid":"16920911","id":"PMC_16920911","title":"Cutting edge: Decreased accumulation and regulatory function of CD4+ CD25(high) T cells in human STAT5b deficiency.","date":"2006","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/16920911","citation_count":181,"is_preprint":false},{"pmid":"10974037","id":"PMC_10974037","title":"Essential role of signal transducer and activator of transcription (Stat)5a but not Stat5b for Flt3-dependent signaling.","date":"2000","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/10974037","citation_count":171,"is_preprint":false},{"pmid":"12682066","id":"PMC_12682066","title":"Acute control of insulin-like growth factor-I gene transcription by growth hormone through Stat5b.","date":"2003","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/12682066","citation_count":161,"is_preprint":false},{"pmid":"8530402","id":"PMC_8530402","title":"Transcription factors Stat3 and Stat5b are present in rat liver nuclei late in an acute phase response and bind interleukin-6 response elements.","date":"1995","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/8530402","citation_count":152,"is_preprint":false},{"pmid":"17030597","id":"PMC_17030597","title":"Characterization of immunodeficiency in a patient with growth hormone insensitivity secondary to a novel STAT5b gene mutation.","date":"2006","source":"Pediatrics","url":"https://pubmed.ncbi.nlm.nih.gov/17030597","citation_count":135,"is_preprint":false},{"pmid":"12429742","id":"PMC_12429742","title":"STAT5b, a Mediator of Synergism between c-Src and the Epidermal Growth Factor Receptor.","date":"2002","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/12429742","citation_count":127,"is_preprint":false},{"pmid":"9742102","id":"PMC_9742102","title":"A sequence of the CIS gene promoter interacts preferentially with two associated STAT5A dimers: a distinct biochemical difference between STAT5A and STAT5B.","date":"1998","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/9742102","citation_count":124,"is_preprint":false},{"pmid":"9422769","id":"PMC_9422769","title":"Granulocyte-macrophage colony-stimulating factor-activated signaling pathways in human neutrophils. Selective activation of Jak2, Stat3, and Stat5b.","date":"1998","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/9422769","citation_count":104,"is_preprint":false},{"pmid":"22912632","id":"PMC_22912632","title":"The STAT5b Pathway Defect and Autoimmunity.","date":"2012","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/22912632","citation_count":100,"is_preprint":false},{"pmid":"10630411","id":"PMC_10630411","title":"STAT5b mediates the GH-induced expression of SOCS-2 and SOCS-3 mRNA in the liver.","date":"1999","source":"Molecular and cellular endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/10630411","citation_count":100,"is_preprint":false},{"pmid":"10428824","id":"PMC_10428824","title":"Differential effects of prolactin and src/abl kinases on the nuclear translocation of STAT5B and STAT5A.","date":"1999","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/10428824","citation_count":98,"is_preprint":false},{"pmid":"14583472","id":"PMC_14583472","title":"Constitutive activation of Stat5b contributes to carcinogenesis in vivo.","date":"2003","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/14583472","citation_count":95,"is_preprint":false},{"pmid":"28887441","id":"PMC_28887441","title":"HIV-1-mediated insertional activation of STAT5B and BACH2 trigger viral reservoir in T regulatory cells.","date":"2017","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/28887441","citation_count":93,"is_preprint":false},{"pmid":"21396575","id":"PMC_21396575","title":"STAT5b deficiency: lessons from STAT5b gene mutations.","date":"2011","source":"Best practice & research. Clinical endocrinology & metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/21396575","citation_count":90,"is_preprint":false},{"pmid":"22361342","id":"PMC_22361342","title":"Mapping the growth hormone--Stat5b--IGF-I transcriptional circuit.","date":"2012","source":"Trends in endocrinology and metabolism: TEM","url":"https://pubmed.ncbi.nlm.nih.gov/22361342","citation_count":89,"is_preprint":false},{"pmid":"29844444","id":"PMC_29844444","title":"Dominant-negative STAT5B mutations cause growth hormone insensitivity with short stature and mild immune dysregulation.","date":"2018","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/29844444","citation_count":86,"is_preprint":false},{"pmid":"10585399","id":"PMC_10585399","title":"STAT5b-deficient mice are growth hormone pulse-resistant. Role of STAT5b in sex-specific liver p450 expression.","date":"1999","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/10585399","citation_count":82,"is_preprint":false},{"pmid":"12588773","id":"PMC_12588773","title":"A functional polymorphism in a STAT5B site of the human PPAR gamma 3 gene promoter affects height and lipid metabolism in a French population.","date":"2003","source":"Arteriosclerosis, thrombosis, and vascular biology","url":"https://pubmed.ncbi.nlm.nih.gov/12588773","citation_count":80,"is_preprint":false},{"pmid":"7559477","id":"PMC_7559477","title":"STAT3 and STAT5B are targets of two different signal pathways activated by hematopoietin receptors and control transcription via separate cytokine response elements.","date":"1995","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/7559477","citation_count":77,"is_preprint":false},{"pmid":"14761873","id":"PMC_14761873","title":"In vivo regulation of growth hormone-stimulated gene transcription by STAT5b.","date":"2004","source":"American journal of physiology. Endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/14761873","citation_count":75,"is_preprint":false},{"pmid":"16787985","id":"PMC_16787985","title":"Clinical and biochemical characteristics of a male patient with a novel homozygous STAT5b mutation.","date":"2006","source":"The Journal of clinical endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/16787985","citation_count":75,"is_preprint":false},{"pmid":"16862179","id":"PMC_16862179","title":"Neurotensin stimulates mitogenesis of prostate cancer cells through a novel c-Src/Stat5b pathway.","date":"2006","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/16862179","citation_count":73,"is_preprint":false},{"pmid":"30573779","id":"PMC_30573779","title":"Recurrent activating STAT5B N642H mutation in myeloid neoplasms with eosinophilia.","date":"2018","source":"Leukemia","url":"https://pubmed.ncbi.nlm.nih.gov/30573779","citation_count":70,"is_preprint":false},{"pmid":"16339156","id":"PMC_16339156","title":"Characterization of distinct Stat5b binding sites that mediate growth hormone-stimulated IGF-I gene transcription.","date":"2005","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/16339156","citation_count":70,"is_preprint":false},{"pmid":"10628751","id":"PMC_10628751","title":"Stat5b inhibits NFkappaB-mediated signaling.","date":"2000","source":"Molecular endocrinology (Baltimore, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/10628751","citation_count":70,"is_preprint":false},{"pmid":"26703237","id":"PMC_26703237","title":"STAT5B deficiency: Impacts on human growth and immunity.","date":"2015","source":"Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society","url":"https://pubmed.ncbi.nlm.nih.gov/26703237","citation_count":68,"is_preprint":false},{"pmid":"24497979","id":"PMC_24497979","title":"Identification of STAT5A and STAT5B target genes in human T cells.","date":"2014","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/24497979","citation_count":68,"is_preprint":false},{"pmid":"24440911","id":"PMC_24440911","title":"Multiple receptor tyrosine kinases converge on microRNA-134 to control KRAS, STAT5B, and glioblastoma.","date":"2014","source":"Cell death and differentiation","url":"https://pubmed.ncbi.nlm.nih.gov/24440911","citation_count":67,"is_preprint":false},{"pmid":"10224108","id":"PMC_10224108","title":"Insulin inhibits growth hormone signaling via the growth hormone receptor/JAK2/STAT5B pathway.","date":"1999","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/10224108","citation_count":67,"is_preprint":false},{"pmid":"10514468","id":"PMC_10514468","title":"STAT5b down-regulates peroxisome proliferator-activated receptor alpha transcription by inhibition of ligand-independent activation function region-1 trans-activation domain.","date":"1999","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/10514468","citation_count":67,"is_preprint":false},{"pmid":"9231797","id":"PMC_9231797","title":"Growth hormone-induced tyrosyl phosphorylation and deoxyribonucleic acid binding activity of Stat5A and Stat5B.","date":"1997","source":"Endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/9231797","citation_count":65,"is_preprint":false},{"pmid":"9892011","id":"PMC_9892011","title":"Termination of growth hormone pulse-induced STAT5b signaling.","date":"1999","source":"Molecular endocrinology (Baltimore, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/9892011","citation_count":64,"is_preprint":false},{"pmid":"20167868","id":"PMC_20167868","title":"Transcription factor Stat3 stimulates metastatic behavior of human prostate cancer cells in vivo, whereas Stat5b has a preferential role in the promotion of prostate cancer cell viability and tumor growth.","date":"2010","source":"The American journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/20167868","citation_count":63,"is_preprint":false},{"pmid":"31175292","id":"PMC_31175292","title":"Structural and functional consequences of the STAT5BN642H driver mutation.","date":"2019","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/31175292","citation_count":62,"is_preprint":false},{"pmid":"11971004","id":"PMC_11971004","title":"Stat5B shuttles between cytoplasm and nucleus in a cytokine-dependent and -independent manner.","date":"2002","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/11971004","citation_count":59,"is_preprint":false},{"pmid":"11731617","id":"PMC_11731617","title":"Serine phosphorylation of GH-activated signal transducer and activator of transcription 5a (STAT5a) and STAT5b: impact on STAT5 transcriptional activity.","date":"2001","source":"Molecular endocrinology (Baltimore, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/11731617","citation_count":59,"is_preprint":false},{"pmid":"9605930","id":"PMC_9605930","title":"Binding of STAT5a and STAT5b to a single element resembling a gamma-interferon-activated sequence mediates the growth hormone induction of the mouse acid-labile subunit promoter in liver cells.","date":"1998","source":"Molecular endocrinology (Baltimore, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/9605930","citation_count":58,"is_preprint":false},{"pmid":"24512550","id":"PMC_24512550","title":"Uncovering the pathogenesis of large granular lymphocytic leukemia-novel STAT3 and STAT5b mutations.","date":"2014","source":"Annals of medicine","url":"https://pubmed.ncbi.nlm.nih.gov/24512550","citation_count":57,"is_preprint":false},{"pmid":"10448095","id":"PMC_10448095","title":"PPARgamma ligand-dependent induction of STAT1, STAT5A, and STAT5B during adipogenesis.","date":"1999","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/10448095","citation_count":57,"is_preprint":false},{"pmid":"9973252","id":"PMC_9973252","title":"Down-regulation of liver JAK2-STAT5b signaling by the female plasma pattern of continuous growth hormone stimulation.","date":"1999","source":"Molecular endocrinology (Baltimore, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/9973252","citation_count":54,"is_preprint":false},{"pmid":"11751923","id":"PMC_11751923","title":"Novel activation of STAT5b in response to epidermal growth factor.","date":"2001","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/11751923","citation_count":54,"is_preprint":false},{"pmid":"25702814","id":"PMC_25702814","title":"Nanomolar inhibitors of the transcription factor STAT5b with high selectivity over STAT5a.","date":"2015","source":"Angewandte Chemie (International ed. in English)","url":"https://pubmed.ncbi.nlm.nih.gov/25702814","citation_count":53,"is_preprint":false},{"pmid":"28100634","id":"PMC_28100634","title":"Cryptochromes regulate IGF-1 production and signaling through control of JAK2-dependent STAT5B phosphorylation.","date":"2017","source":"Molecular biology of the cell","url":"https://pubmed.ncbi.nlm.nih.gov/28100634","citation_count":52,"is_preprint":false},{"pmid":"12869640","id":"PMC_12869640","title":"Down-regulation of STAT5b transcriptional activity by ligand-activated peroxisome proliferator-activated receptor (PPAR) alpha and PPARgamma.","date":"2003","source":"Molecular pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/12869640","citation_count":49,"is_preprint":false},{"pmid":"20538865","id":"PMC_20538865","title":"A novel STAT5B mutation causing GH insensitivity syndrome associated with hyperprolactinemia and immune dysfunction in two male siblings.","date":"2010","source":"European journal of endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/20538865","citation_count":49,"is_preprint":false},{"pmid":"33255665","id":"PMC_33255665","title":"STAT3 and STAT5B Mutations in T/NK-Cell Chronic Lymphoproliferative Disorders of Large Granular Lymphocytes (LGL): Association with Disease Features.","date":"2020","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/33255665","citation_count":48,"is_preprint":false},{"pmid":"22485142","id":"PMC_22485142","title":"Methylsulfonylmethane suppresses breast cancer growth by down-regulating STAT3 and STAT5b pathways.","date":"2012","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/22485142","citation_count":47,"is_preprint":false},{"pmid":"26959237","id":"PMC_26959237","title":"Chemical and Hormonal Effects on STAT5b-Dependent Sexual Dimorphism of the Liver Transcriptome.","date":"2016","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/26959237","citation_count":45,"is_preprint":false},{"pmid":"30679796","id":"PMC_30679796","title":"Twins with different personalities: STAT5B-but not STAT5A-has a key role in BCR/ABL-induced leukemia.","date":"2019","source":"Leukemia","url":"https://pubmed.ncbi.nlm.nih.gov/30679796","citation_count":45,"is_preprint":false},{"pmid":"15364543","id":"PMC_15364543","title":"Simultaneous, bidirectional inhibitory crosstalk between PPAR and STAT5b.","date":"2004","source":"Toxicology and applied pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/15364543","citation_count":45,"is_preprint":false},{"pmid":"23773921","id":"PMC_23773921","title":"Differentiating the roles of STAT5B and STAT5A in human CD4+ T cells.","date":"2013","source":"Clinical immunology (Orlando, Fla.)","url":"https://pubmed.ncbi.nlm.nih.gov/23773921","citation_count":44,"is_preprint":false},{"pmid":"36755813","id":"PMC_36755813","title":"STAT5b: A master regulator of key biological pathways.","date":"2023","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/36755813","citation_count":44,"is_preprint":false},{"pmid":"35210405","id":"PMC_35210405","title":"Identification of novel STAT5B mutations and characterization of TCRβ signatures in CD4+ T-cell large granular lymphocyte leukemia.","date":"2022","source":"Blood cancer journal","url":"https://pubmed.ncbi.nlm.nih.gov/35210405","citation_count":43,"is_preprint":false},{"pmid":"26959975","id":"PMC_26959975","title":"Disruption of STAT5b-Regulated Sexual Dimorphism of the Liver Transcriptome by Diverse Factors Is a Common Event.","date":"2016","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/26959975","citation_count":43,"is_preprint":false},{"pmid":"28400581","id":"PMC_28400581","title":"Rational development of Stafib-2: a selective, nanomolar inhibitor of the transcription factor STAT5b.","date":"2017","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/28400581","citation_count":43,"is_preprint":false},{"pmid":"12039059","id":"PMC_12039059","title":"The structure of human STAT5A and B genes reveals two regions of nearly identical sequence and an alternative tissue specific STAT5B promoter.","date":"2002","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/12039059","citation_count":42,"is_preprint":false},{"pmid":"20639532","id":"PMC_20639532","title":"A novel role of CPEB3 in regulating EGFR gene transcription via association with Stat5b in neurons.","date":"2010","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/20639532","citation_count":39,"is_preprint":false},{"pmid":"22729867","id":"PMC_22729867","title":"Nuclear EGFRvIII-STAT5b complex contributes to glioblastoma cell survival by direct activation of the Bcl-XL promoter.","date":"2012","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/22729867","citation_count":38,"is_preprint":false},{"pmid":"10720694","id":"PMC_10720694","title":"Thrombopoietin induces the generation of distinct Stat1, Stat3, Stat5a and Stat5b homo- and heterodimeric complexes with different kinetics in human platelets.","date":"2000","source":"Experimental hematology","url":"https://pubmed.ncbi.nlm.nih.gov/10720694","citation_count":38,"is_preprint":false},{"pmid":"14701862","id":"PMC_14701862","title":"A mutant Stat5b with weaker DNA binding affinity defines a key defective pathway in nonobese diabetic mice.","date":"2003","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/14701862","citation_count":37,"is_preprint":false},{"pmid":"23097626","id":"PMC_23097626","title":"STAT5b as molecular target in pancreatic cancer--inhibition of tumor growth, angiogenesis, and metastases.","date":"2012","source":"Neoplasia (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/23097626","citation_count":37,"is_preprint":false},{"pmid":"24470975","id":"PMC_24470975","title":"JAK2-STAT5B pathway and osteoblast differentiation.","date":"2013","source":"JAK-STAT","url":"https://pubmed.ncbi.nlm.nih.gov/24470975","citation_count":36,"is_preprint":false},{"pmid":"29377304","id":"PMC_29377304","title":"Regulation of human trophoblast cell syncytialization by transcription factors STAT5B and NR4A3.","date":"2018","source":"Journal of cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/29377304","citation_count":35,"is_preprint":false},{"pmid":"16155412","id":"PMC_16155412","title":"Hypoxia activates the cyclin D1 promoter via the Jak2/STAT5b pathway in breast cancer cells.","date":"2005","source":"Experimental & molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/16155412","citation_count":35,"is_preprint":false},{"pmid":"16527988","id":"PMC_16527988","title":"Novel role for STAT-5B in the regulation of Hsp27-FGF-2 axis facilitating thrombin-induced vascular smooth muscle cell growth and motility.","date":"2006","source":"Circulation research","url":"https://pubmed.ncbi.nlm.nih.gov/16527988","citation_count":35,"is_preprint":false},{"pmid":"10984246","id":"PMC_10984246","title":"Pulsatility of growth hormone (GH) signalling in liver cells: role of the JAK-STAT5b pathway in GH action.","date":"2000","source":"Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society","url":"https://pubmed.ncbi.nlm.nih.gov/10984246","citation_count":34,"is_preprint":false},{"pmid":"29187589","id":"PMC_29187589","title":"STAT5B: A Differential Regulator of the Life and Death of CD4+ Effector Memory T Cells.","date":"2017","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/29187589","citation_count":32,"is_preprint":false},{"pmid":"19630967","id":"PMC_19630967","title":"A novel role for signal transducer and activator of transcription 5b (STAT5b) in beta1-integrin-mediated human breast cancer cell migration.","date":"2009","source":"Breast cancer research : BCR","url":"https://pubmed.ncbi.nlm.nih.gov/19630967","citation_count":32,"is_preprint":false},{"pmid":"22442148","id":"PMC_22442148","title":"Signal transducer and activator of transcription 5b (Stat5b) serine 193 is a novel cytokine-induced phospho-regulatory site that is constitutively activated in primary hematopoietic malignancies.","date":"2012","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/22442148","citation_count":32,"is_preprint":false},{"pmid":"33122102","id":"PMC_33122102","title":"Human growth disorders associated with impaired GH action: Defects in STAT5B and JAK2.","date":"2020","source":"Molecular and cellular endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/33122102","citation_count":31,"is_preprint":false},{"pmid":"15043997","id":"PMC_15043997","title":"Characterization of the human STAT5A and STAT5B promoters: evidence of a positive and negative mechanism of transcriptional regulation.","date":"2004","source":"FEBS letters","url":"https://pubmed.ncbi.nlm.nih.gov/15043997","citation_count":30,"is_preprint":false},{"pmid":"20702587","id":"PMC_20702587","title":"ZFP36L1 negatively regulates erythroid differentiation of CD34+ hematopoietic stem cells by interfering with the Stat5b pathway.","date":"2010","source":"Molecular biology of the cell","url":"https://pubmed.ncbi.nlm.nih.gov/20702587","citation_count":30,"is_preprint":false},{"pmid":"17509524","id":"PMC_17509524","title":"Hypoxia activates the IGF-1 expression through STAT5b in human HepG2 cells.","date":"2007","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/17509524","citation_count":28,"is_preprint":false},{"pmid":"29246863","id":"PMC_29246863","title":"Essential roles of stat5.1/stat5b in controlling fish somatic growth.","date":"2017","source":"Journal of genetics and genomics = Yi chuan xue bao","url":"https://pubmed.ncbi.nlm.nih.gov/29246863","citation_count":27,"is_preprint":false},{"pmid":"26388045","id":"PMC_26388045","title":"Signal transducer and activator of transcription 5B (STAT5B) modulates adipocyte differentiation via MOF.","date":"2015","source":"Cellular signalling","url":"https://pubmed.ncbi.nlm.nih.gov/26388045","citation_count":27,"is_preprint":false},{"pmid":"35469842","id":"PMC_35469842","title":"STAT5B restrains human B-cell differentiation to maintain humoral immune homeostasis.","date":"2022","source":"The Journal of allergy and clinical immunology","url":"https://pubmed.ncbi.nlm.nih.gov/35469842","citation_count":26,"is_preprint":false},{"pmid":"24836440","id":"PMC_24836440","title":"BCR-ABL affects STAT5A and STAT5B differentially.","date":"2014","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/24836440","citation_count":26,"is_preprint":false},{"pmid":"34716993","id":"PMC_34716993","title":"miR-146a enhances regulatory T-cell differentiation and function in allergic rhinitis by targeting STAT5b.","date":"2021","source":"Allergy","url":"https://pubmed.ncbi.nlm.nih.gov/34716993","citation_count":26,"is_preprint":false},{"pmid":"16584384","id":"PMC_16584384","title":"Signalling cross-talk between hepatocyte nuclear factor 4alpha and growth-hormone-activated STAT5b.","date":"2006","source":"The Biochemical journal","url":"https://pubmed.ncbi.nlm.nih.gov/16584384","citation_count":26,"is_preprint":false},{"pmid":"21431790","id":"PMC_21431790","title":"Constitutively active Stat5A and Stat5B promote adipogenesis.","date":"2010","source":"Environmental health and preventive medicine","url":"https://pubmed.ncbi.nlm.nih.gov/21431790","citation_count":26,"is_preprint":false},{"pmid":"18695876","id":"PMC_18695876","title":"Enhancement of hypoxia-induced apoptosis of human breast cancer cells via STAT5b by momilactone B.","date":"2008","source":"International journal of oncology","url":"https://pubmed.ncbi.nlm.nih.gov/18695876","citation_count":26,"is_preprint":false},{"pmid":"11781356","id":"PMC_11781356","title":"Diabetic LDL inhibits cell-cycle progression via STAT5B and p21(waf).","date":"2002","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/11781356","citation_count":23,"is_preprint":false},{"pmid":"29988287","id":"PMC_29988287","title":"Primary Immunodeficiencies Unravel the Role of IL-2/CD25/STAT5b in Human Natural Killer Cell Maturation.","date":"2018","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/29988287","citation_count":23,"is_preprint":false},{"pmid":"27035235","id":"PMC_27035235","title":"Suppression of STAT5b in pancreatic cancer cells leads to attenuated gemcitabine chemoresistance, adhesion and invasion.","date":"2016","source":"Oncology reports","url":"https://pubmed.ncbi.nlm.nih.gov/27035235","citation_count":22,"is_preprint":false},{"pmid":"26469307","id":"PMC_26469307","title":"Phosphorylation of Capsaicinoid Derivatives Provides Highly Potent and Selective Inhibitors of the Transcription Factor STAT5b.","date":"2015","source":"ACS chemical biology","url":"https://pubmed.ncbi.nlm.nih.gov/26469307","citation_count":22,"is_preprint":false},{"pmid":"24335105","id":"PMC_24335105","title":"Constitutive activation of STAT5A and STAT5B regulates IgM secretion in Waldenstrom's macroglobulinemia.","date":"2013","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/24335105","citation_count":21,"is_preprint":false},{"pmid":"17287404","id":"PMC_17287404","title":"Growth hormone secretion and immunological function of a male patient with a homozygous STAT5b mutation.","date":"2007","source":"European journal of endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/17287404","citation_count":21,"is_preprint":false},{"pmid":"22919439","id":"PMC_22919439","title":"Coffee polyphenols change the expression of STAT5B and ATF-2 modifying cyclin D1 levels in cancer cells.","date":"2012","source":"Oxidative medicine and cellular longevity","url":"https://pubmed.ncbi.nlm.nih.gov/22919439","citation_count":19,"is_preprint":false},{"pmid":"28612433","id":"PMC_28612433","title":"Musculin inhibits human T-helper 17 cell response to interleukin 2 by controlling STAT5B activity.","date":"2017","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/28612433","citation_count":19,"is_preprint":false},{"pmid":"16959781","id":"PMC_16959781","title":"Retracted: Glucocorticoids repress bcl-X expression in lymphoid cells by recruiting STAT5B to the P4 promoter.","date":"2006","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/16959781","citation_count":18,"is_preprint":false},{"pmid":"9528973","id":"PMC_9528973","title":"Lactogenic hormone-inducible phosphorylation and gamma-activated site-binding activities of Stat5b in primary rat Leydig cells and MA-10 mouse Leydig tumor cells.","date":"1998","source":"Endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/9528973","citation_count":17,"is_preprint":false},{"pmid":"16531819","id":"PMC_16531819","title":"Constitutively active STAT5b induces cytokine-independent growth of the acute myeloid leukemia-derived MUTZ-3 cell line and accelerates its differentiation into mature dendritic cells.","date":"2006","source":"Journal of immunotherapy (Hagerstown, Md. : 1997)","url":"https://pubmed.ncbi.nlm.nih.gov/16531819","citation_count":17,"is_preprint":false},{"pmid":"10329425","id":"PMC_10329425","title":"EGF-induced activation of Stat1, Stat3, and Stat5b is unrelated to the stimulation of DNA synthesis in cultured hepatocytes.","date":"1999","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/10329425","citation_count":17,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":50682,"output_tokens":9844,"usd":0.149853},"stage2":{"model":"claude-opus-4-6","input_tokens":13818,"output_tokens":4485,"usd":0.271823},"total_usd":0.421676,"stage1_batch_id":"msgbatch_011rkcQdVV1RaFq9XhcG6df6","stage2_batch_id":"msgbatch_01RzgrJafdF4EWHhj5mNi6dh","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1996,\n      \"finding\": \"STAT5A and STAT5B are activated by tyrosine phosphorylation in mammary tissue during lactation; upon phosphorylation, they form homo- and heterodimers that bind DNA and drive milk protein gene transcription. Phosphorylation correlates tightly with mammary gland differentiation.\",\n      \"method\": \"Isoform-specific antibodies, EMSA, supershift analysis, transgenic mice\",\n      \"journal\": \"Molecular endocrinology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods (antibody-based detection, EMSA, in vivo transgenic model) in a single rigorous study\",\n      \"pmids\": [\"8961260\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"GH induces tyrosine phosphorylation of both STAT5A and STAT5B via JAK2 kinase, requiring specific cytoplasmic regions of the GH receptor (C-terminal half; tyrosines 333/338); JAK2 is required for GH-dependent STAT5B tyrosine phosphorylation.\",\n      \"method\": \"Transient transfection in COS cells and CHO cells expressing truncated/mutated GH receptors, JAK2-deficient cell lines, Western blotting\",\n      \"journal\": \"Endocrinology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1/2 — reconstitution with receptor mutants + JAK2-deficient cells, multiple cell systems\",\n      \"pmids\": [\"9231797\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"STAT5B, but not STAT5A, is essential for NK cell-mediated proliferation and cytolytic activity in response to IL-2 and IL-15; Stat5b-/- mice show diminished IL-2 receptor beta chain expression, reduced NK cell numbers and responsiveness.\",\n      \"method\": \"Stat5b knockout mice, proliferation assays, NK cytolytic activity assays\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — clean KO with defined cellular phenotype, multiple functional readouts\",\n      \"pmids\": [\"9841920\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"The CIS gene promoter contains paired STAT binding elements that bind STAT5 tetramers; STAT5A (but not STAT5B) can form tetrameric complexes on adjacent STAT sites, representing a biochemical distinction between the two isoforms. STAT5B binds as a homodimer with higher affinity than STAT5A.\",\n      \"method\": \"EMSA with nuclear extracts and purified recombinant proteins, transient transfection with STAT5A/B expression vectors, COS-7 cell model\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — reconstitution with purified proteins + mutant analysis, replicated in cell extracts\",\n      \"pmids\": [\"9742102\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"GM-CSF selectively activates JAK2, STAT3, and STAT5B (not STAT5A, STAT1, STAT2, STAT4, or STAT6) in human neutrophils; only the 92-kDa STAT5B isoform undergoes tyrosine phosphorylation and increased DNA binding in response to GM-CSF.\",\n      \"method\": \"Immunoprecipitation, Western blot, EMSA with isoform-specific antibodies\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — reciprocal pulldown/IP with isoform-specific antibodies and EMSA, single lab but multiple orthogonal methods\",\n      \"pmids\": [\"9422769\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"STAT5A and STAT5B bind to a single GAS-like element (ALS-GAS1) in the mouse acid-labile subunit (ALS) promoter in a GH-dependent manner, mediating GH-induced transcription of the ALS gene in hepatocytes.\",\n      \"method\": \"Promoter deletion analysis, luciferase reporter assays, EMSA with supershift using STAT5 antibodies, primary rat hepatocytes and H4-II-E hepatoma cells\",\n      \"journal\": \"Molecular endocrinology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1/2 — reporter assays with deletion mutants, EMSA supershift, primary cells\",\n      \"pmids\": [\"9605930\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"GH and PRL activate STAT5B via JAK2 tyrosine phosphorylation in Leydig cells, inducing STAT5B nuclear translocation and DNA binding to GAS elements; the response is cell-type specific (immature but not adult primary Leydig cells respond to GH).\",\n      \"method\": \"Immunoprecipitation, Western blot, EMSA, primary rat Leydig cells and MA-10 mouse Leydig tumor cells\",\n      \"journal\": \"Endocrinology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple biochemical methods, single lab\",\n      \"pmids\": [\"9528973\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"STAT5b mediates GH-induced expression of SOCS-2 and SOCS-3 mRNA in liver but not in mammary gland, demonstrating tissue-specific STAT5b-dependent feedback regulation of GH signaling.\",\n      \"method\": \"STAT5b knockout mice, GH treatment, Northern blot/mRNA quantification\",\n      \"journal\": \"Molecular and cellular endocrinology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — clean KO with specific molecular readout, tissue specificity demonstrated\",\n      \"pmids\": [\"10630411\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"Src kinase activates STAT5B by tyrosine phosphorylation leading to its nuclear translocation, but this occurs by a mechanism distinct from JAK-mediated cytokine activation: src-mediated STAT5B nuclear translocation does not depend on JAK2, is selective for STAT5B over STAT5A, and is mediated by C-terminal sequences of STAT5B. Src-activated STAT5B does not drive beta-casein promoter transcription despite nuclear translocation.\",\n      \"method\": \"Dominant-negative JAK2 overexpression, indirect immunofluorescence, co-transfection reporter assays\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods (immunofluorescence, dominant-negative, reporter assay) demonstrating mechanistic distinction\",\n      \"pmids\": [\"10428824\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"Termination of GH pulse-induced STAT5b signaling requires synthesis of a labile protein factor (sensitive to cycloheximide), proteasome activity (sensitive to MG132), and phosphotyrosine phosphatase activity (sensitive to pervanadate); serine kinase inhibitor H7 sustains JAK2 signaling to STAT5b.\",\n      \"method\": \"CWSV-1 rat liver cell line, pharmacological inhibitors (cycloheximide, MG132, pervanadate, H7), GH pulse protocols\",\n      \"journal\": \"Molecular endocrinology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple pharmacological dissection with defined mechanistic readouts, coherent model\",\n      \"pmids\": [\"9892011\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"STAT5b is essential for GH pulse-dependent activation of male-specific liver P450 gene expression (CYP2D9) and body weight gain; STAT5b-deficient mice are GH pulse-resistant, demonstrating STAT5b is the key intracellular mediator of pulsatile GH effects in liver.\",\n      \"method\": \"STAT5b knockout mice, hypophysectomy + pulsatile GH replacement, liver gene expression analysis\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — clean KO + hormone replacement experiment with specific molecular and physiological readouts\",\n      \"pmids\": [\"10585399\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"Continuous (female-pattern) GH exposure down-regulates JAK2-STAT5b signaling in liver cells through enhanced dephosphorylation of both STAT5b and GHR-JAK2, with the JAK2 dephosphorylation leading to receptor internalization/degradation.\",\n      \"method\": \"CWSV-1 liver cell line, pharmacological inhibitors (pervanadate, proteasome inhibitors), continuous vs. pulsatile GH treatment protocols\",\n      \"journal\": \"Molecular endocrinology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple pharmacological probes with mechanistic dissection, consistent model\",\n      \"pmids\": [\"9973252\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"GH-activated STAT5b inhibits PPARalpha transcription by targeting the ligand-independent AF-1 transactivation domain of PPARalpha; a constitutively active STAT5b mutant does not inhibit PPARalpha, and SOCS-3 abolishes the inhibitory response.\",\n      \"method\": \"Transient transfection, luciferase reporter assays, GAL4-chimeric receptor constructs, constitutively active and dominant-negative STAT5b mutants\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1/2 — multiple domain-dissection reporter assays with mutants, mechanistic pathway placement\",\n      \"pmids\": [\"10514468\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"STAT5a (but not STAT5b, STAT1–4, or STAT6) is potently activated by Flt3 ligand (FL) downstream of Flt3 receptor kinase without Jak activation; FL does not stimulate hematopoietic progenitor proliferation in Stat5a-/- mice but does in Stat5b-/- mice, demonstrating functional non-redundancy.\",\n      \"method\": \"Baf3/Flt3 stable cell line, EMSA, Stat5a-/- and Stat5b-/- mouse bone marrow progenitor assays\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — epistasis via KO mice + in vitro assays, replicated across cell types\",\n      \"pmids\": [\"10974037\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"PRL-inducible STAT5b inhibits NFκB-mediated signaling independently of STAT5b-DNA interactions but requiring the carboxyl terminus of STAT5b and nuclear translocation; the inhibition is reversed by overexpression of p300/CBP coactivator, suggesting competition for limiting coactivators.\",\n      \"method\": \"Transient transfection, luciferase reporter assays, dominant-negative STAT5b, p300/CBP overexpression\",\n      \"journal\": \"Molecular endocrinology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple functional assays with domain/mutant dissection, coherent mechanistic model\",\n      \"pmids\": [\"10628751\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"EGF activates STAT5b at three novel tyrosine sites (Tyr-725, Tyr-740, Tyr-743) in addition to Tyr-699; Tyr-699 is absolutely required for transcriptional activation while tyrosines 725, 740, 743 may negatively regulate transcription. EGF-induced STAT5b activation requires EGFR overexpression.\",\n      \"method\": \"Metabolic labeling, site-directed mutagenesis, luciferase reporter assays, stable EGFR-overexpressing HEK293 cells\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro mutagenesis + metabolic labeling + reporter assays\",\n      \"pmids\": [\"11751923\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"STAT5b serine phosphorylation at Ser730 contributes to GH-stimulated transcriptional activity in a promoter context-dependent manner; mutation of Ser730 to Ala reduces reporter activity ~50% at an isolated STAT5-binding site but causes ~2-fold higher activity at the intact beta-casein promoter.\",\n      \"method\": \"Mass spectrometry, site-directed mutagenesis, GH-stimulated luciferase reporter assays, serine kinase inhibitor H7\",\n      \"journal\": \"Molecular endocrinology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — mass spectrometry site identification + mutagenesis functional validation\",\n      \"pmids\": [\"11731617\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"STAT5B mediates synergism between EGFR and c-Src: EGF-induced STAT5b tyrosine phosphorylation requires EGFR Tyr845 (a c-Src phosphorylation site), and dominant-negative STAT5b abolishes EGF-induced DNA synthesis, placing STAT5b downstream of the EGFR/c-Src axis.\",\n      \"method\": \"Tyrosine-to-phenylalanine receptor mutants, dominant-negative STAT5b, kinase-defective c-Src, luciferase reporter assays, DNA synthesis assays in human breast tumor cell lines\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple mutants + functional readouts, clear epistatic placement\",\n      \"pmids\": [\"12429742\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"STAT5B shuttles between nucleus and cytoplasm via two distinct mechanisms: (1) a constitutive, cytokine-independent monomer import (requiring the coiled-coil domain, sensitive to leptomycin B indicating CRM1-dependent export), and (2) a cytokine-stimulated, tyrosine phosphorylation/dimerization-dependent import.\",\n      \"method\": \"Leptomycin B treatment, STAT5B Tyr699 mutant (dimerization-defective), deletion mutants, immunofluorescence in Ba/F3 cells\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple mutants + pharmacological dissection + localization imaging\",\n      \"pmids\": [\"11971004\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"STAT5b is a key component of GH-stimulated IGF-I gene transcription in vivo: dominant-negative STAT5b completely prevents GH-stimulated IGF-I gene transcription in rat liver, while constitutively active STAT5b drives IGF-I expression in the absence of hormone.\",\n      \"method\": \"In vivo adenovirus-mediated gene transfer to pituitary-deficient rats, IGF-I mRNA quantification, constitutively active and dominant-negative STAT5b\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — in vivo gene transfer with dominant-negative and constitutively active mutants, rigorous controls\",\n      \"pmids\": [\"12682066\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"A Stat5b mutation (L327M) in NOD mice reduces DNA-binding affinity (Leu327 is the first residue in the STAT DNA-binding domain, conserved in all STATs), leading to decreased expression of Stat5b-regulated target genes IL-2Rβ and Pim1.\",\n      \"method\": \"Sequencing, homology modeling, DNA-protein binding assays, Western blotting\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — structural modeling + binding assay + gene expression, single lab\",\n      \"pmids\": [\"14701862\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"Constitutive activation of Stat5b contributes to squamous cell carcinogenesis in vivo; Stat5b antisense blockade inhibits tumor growth and abrogates Stat5 target gene expression in xenografts. EGFR links to Stat5b in vivo.\",\n      \"method\": \"Antisense oligonucleotide blockade in xenograft model, gene expression analysis\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — in vivo loss-of-function with specific molecular readout, single lab\",\n      \"pmids\": [\"14583472\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"In vivo, dominant-negative STAT5b completely inhibits GH-stimulated transcription of IGF-I, IGFBP-3, ALS, SOCS-1, SOCS-2, and CIS genes in rat liver, but has little effect on SOCS-3. Constitutively active STAT5b drives IGF-I, ALS, and IGFBP-3 without hormone but minimally affects SOCS family induction.\",\n      \"method\": \"In vivo adenovirus-mediated gene transfer to pituitary-deficient male rats, gene expression analysis, dominant-negative and constitutively active STAT5b\",\n      \"journal\": \"American journal of physiology. Endocrinology and metabolism\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — in vivo gene transfer with gain/loss of function, multiple target gene readouts\",\n      \"pmids\": [\"14761873\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"STAT5b and HNF4alpha exhibit bidirectional cross-talk in liver: HNF4alpha inhibits STAT5b transcriptional activity by blocking GH-stimulated JAK2 tyrosine phosphorylation (not STAT5b dephosphorylation), while STAT5b synergistically enhances HNF4alpha activity at the ApoCIII promoter.\",\n      \"method\": \"Transient transfection reporter assays in HepG2 cells, dominant-negative phosphatase 1B, pervanadate treatment, Western blot for JAK2 and STAT5b phosphorylation\",\n      \"journal\": \"The Biochemical journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods, mechanistic dissection at JAK2 level\",\n      \"pmids\": [\"16584384\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"Stat5b binds two distinct GH response elements in the rat IGF-I locus in vivo in a GH-dependent manner (chromatin immunoprecipitation); each element contains one high-affinity and one lower-affinity Stat5b site; paired Stat5b sites in intron 2 are more than twice as effective as the 5'-distal element in driving transcription.\",\n      \"method\": \"Chromatin immunoprecipitation (ChIP), quantitative protein-DNA binding studies, biochemical reconstitution reporter assays\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1/2 — ChIP in vivo + quantitative binding + reconstitution reporter assays\",\n      \"pmids\": [\"16339156\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"STAT5b is required for the in vivo accumulation and regulatory function of CD4+CD25high T regulatory cells; STAT5b(A630P) missense mutation in a patient leads to low FOXP3 expression, impaired Treg suppression, and reduced CD25 expression in response to IL-2.\",\n      \"method\": \"Patient study with homozygous STAT5b missense mutation, flow cytometry, functional Treg assays, in vitro IL-2 stimulation\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — human mutation with multiple functional readouts; unique human model\",\n      \"pmids\": [\"16920911\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"STAT5b mediates neurotensin-induced mitogenesis in prostate cancer cells via a c-Src/EGFR Tyr845/STAT5b pathway; mutant forms of EGFR (Y845F) or STAT5b, or catalytic inhibitors of EGFR, c-Src, and MMPs, abrogate NT-induced DNA synthesis.\",\n      \"method\": \"Site-directed mutant EGFR and STAT5b expression, selective kinase inhibitors, BrdU incorporation/cell counting, PC3 prostate cancer cells\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple mutants + inhibitors + functional proliferation assay, epistatic pathway established\",\n      \"pmids\": [\"16862179\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"Thrombin activates STAT5B (not STAT5A) to induce Hsp27 and FGF-2 expression in vascular smooth muscle cells (VSMC), mediating VSMC growth and motility; STAT5B associates with STAT3 in response to thrombin.\",\n      \"method\": \"Dominant-negative adenoviral STAT5B/STAT5A constructs, siRNA against Hsp27, dominant-negative STAT3, co-immunoprecipitation, VSMC growth and motility assays\",\n      \"journal\": \"Circulation research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — isoform-specific dominant-negatives + RNAi + Co-IP, multiple functional readouts\",\n      \"pmids\": [\"16527988\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"Nuclear EGFRvIII forms a complex with phosphorylated STAT5b, binds DNA, and cooperates with STAT5b to regulate the Bcl-XL promoter; STAT5b knockdown reduces Bcl-XL levels and sensitizes glioblastoma cells to cisplatin.\",\n      \"method\": \"Co-immunoprecipitation of nuclear EGFR-STAT5b, ChIP on Bcl-XL and Aurora A promoters, shRNA knockdown, cisplatin sensitivity assays\",\n      \"journal\": \"International journal of cancer\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — nuclear Co-IP + ChIP + loss-of-function with functional consequence\",\n      \"pmids\": [\"22729867\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"Glucocorticoids recruit STAT5B to the P4 promoter of bcl-X in lymphoid cells where it acts as a persistent repressor; inhibition of STAT5 activity converts glucocorticoid-induced repression to activation, associated with stable GR and RNA Pol II recruitment.\",\n      \"method\": \"ChIP, transient transfection reporter assays, STAT5 inhibition in S49 T cells and mouse thymocytes\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — ChIP + reporter assays, but paper is retracted\",\n      \"pmids\": [\"16959781\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"CPEB3 interacts with STAT5b in the nucleus and inhibits its transcriptional activity without disrupting STAT5b dimerization, DNA binding, or nuclear localization; EGFR is a direct transcriptional target of STAT5b in neurons, negatively regulated by CPEB3.\",\n      \"method\": \"Co-immunoprecipitation of CPEB3-STAT5b, STAT5b knockdown, reporter assays, NMDA receptor activation, neuronal CPEB3 nuclear accumulation\",\n      \"journal\": \"Nucleic acids research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — Co-IP + reporter assays + KD with target gene readout, multiple methods\",\n      \"pmids\": [\"20639532\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"ZFP36L1 negatively regulates erythroid differentiation of CD34+ hematopoietic stem cells by directly binding the 3'-UTR of STAT5b mRNA and triggering its degradation, thereby down-regulating STAT5b protein and suppressing erythroid colony formation.\",\n      \"method\": \"ZFP36L1 overexpression, siRNA knockdown, 3'-UTR binding assay, erythroid colony formation assay\",\n      \"journal\": \"Molecular biology of the cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — direct 3'-UTR binding + KD/OE with functional colony assay\",\n      \"pmids\": [\"20702587\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"Stat5b has a predominant role over Stat5a in promoting prostate cancer cell viability and tumor growth; inhibition of Stat5a/b induces massive cancer cell death and reduces subcutaneous and orthotopic tumor growth in vivo, while Stat3 dominates metastasis promotion.\",\n      \"method\": \"siRNA knockdown, subcutaneous and orthotopic xenograft models, RNA-seq gene expression profiling\",\n      \"journal\": \"The American journal of pathology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — isoform-specific KD with in vivo tumor models and molecular profiling\",\n      \"pmids\": [\"20167868\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"STAT5b Ser-193 is a novel cytokine-induced phosphorylation site identified by mass spectrometry; it is phosphorylated rapidly in the cytoplasm prior to nuclear translocation, requires mTOR kinase and PP2A dephosphorylates it, and is required for maximal STAT5b transcriptional activity.\",\n      \"method\": \"Mass spectrometry, phospho-specific antibodies, mTOR and PP2A inhibitors, site-directed mutagenesis, EMSA, reporter assays, HEK293 reconstitution\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — mass spectrometry site ID + mutagenesis + kinase/phosphatase inhibitor dissection + reporter assay\",\n      \"pmids\": [\"22442148\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Somatic STAT5B mutations (Y665F, N642H) in the SH2 domain increase STAT5 tyrosine phosphorylation and transcriptional activity in LGL leukemia cells, representing the first somatic STAT5 gain-of-function mutations discovered in human cancer.\",\n      \"method\": \"Exome and transcriptome sequencing, targeted amplicon sequencing, transfection of mutant constructs with phosphorylation and transcriptional activity assays\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — sequencing + functional validation of mutant constructs with molecular readouts\",\n      \"pmids\": [\"23596048\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"STAT5B N642H mutation in the SH2 domain causes markedly increased binding affinity of phosphotyrosine-Y699 with the mutant histidine (surface plasmon resonance), prolonged persistence of phospho-STAT5B, and increased binding to target sites, conferring growth advantage to NK and γδ-T cells.\",\n      \"method\": \"Molecular modelling, surface plasmon resonance, next-generation sequencing, transduction of cell lines and primary NK cells, JAK1/2 inhibitor treatment\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1/2 — biophysical SPR measurement + structural modeling + functional cell assays\",\n      \"pmids\": [\"25586472\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"The STAT5b SH2 domain can be selectively inhibited over STAT5a (>50-fold) by the natural product-inspired small molecule Stafib-1 (Ki=44 nM); binding site validated by point mutant functional analysis.\",\n      \"method\": \"In vitro SH2 domain binding assay, point mutant analysis, tumor cell phosphorylation inhibition\",\n      \"journal\": \"Angewandte Chemie\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1/2 — biochemical binding assay with mutants + cellular validation\",\n      \"pmids\": [\"25702814\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"Cryptochromes regulate IGF-1 production by controlling JAK2-dependent STAT5B phosphorylation at Y699 in liver and skeletal muscle; CRY deficiency reduces STAT5B Y699 phosphorylation without reducing JAK2 phosphorylation, placing CRY function downstream of JAK2 in the GH-STAT5B-IGF-1 axis.\",\n      \"method\": \"Cry-deficient mice, phospho-specific antibodies, IGF-1 ELISA, qPCR\",\n      \"journal\": \"Molecular biology of the cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic KO with phosphorylation-level epistasis and multiple readouts\",\n      \"pmids\": [\"28100634\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"Musculin (MSC) expressed in human Th17 cells in an RORγt-dependent manner upregulates PPP2R2B (PP2A regulatory subunit), which dephosphorylates STAT5B Ser-193, thereby reducing STAT5B transcriptional activity and IL-2 responsiveness in Th17 cells.\",\n      \"method\": \"Th17 cell expression analysis, PP2A inhibitor experiments, Ser-193 phosphorylation assay, gene reporter assays\",\n      \"journal\": \"European journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — mechanistic pathway linking MSC→PP2A→pSer193-STAT5B→reduced transcription, multiple methods\",\n      \"pmids\": [\"28612433\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Dominant-negative STAT5B missense mutants are tyrosine phosphorylated but fail to localize to the nucleus or fail to bind canonical DNA response elements; each retains the ability to dimerize with wild-type STAT5B, thereby disrupting wild-type STAT5B transcriptional function through dominant-negative mechanism.\",\n      \"method\": \"Patient germline mutations, nuclear localization assays, EMSA for DNA binding, dimerization assays, transcriptional reporter assays\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple mutants with distinct mechanistic defects identified by orthogonal assays in patient-derived and transfected cells\",\n      \"pmids\": [\"29844444\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"cAMP-PKA signaling upregulates STAT5B in human trophoblast cells, and STAT5B knockdown decreases FSK-induced cell fusion and expression of syncytialization markers (CGB, syncytin2, GCM1, OVOL1), establishing STAT5B as a positive regulator of trophoblast syncytialization.\",\n      \"method\": \"siRNA knockdown of STAT5B, microarray, qPCR, syncytialization functional assays in BeWo cells\",\n      \"journal\": \"Journal of cellular biochemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — single KD approach with functional readout, single lab\",\n      \"pmids\": [\"29377304\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Crystal structures of human STAT5B and STAT5B-N642H reveal alternative SH2 domain conformations; biophysical data suggests the N642H mutant can adopt hyper-activated and hyper-inactivated states with resistance to dephosphorylation; MD simulations support sustained interchain cross-domain interactions in the N642H anti-parallel dimer.\",\n      \"method\": \"X-ray crystallography (human STAT5B and N642H crystal structures), biophysical assays, molecular dynamics simulations, transgenic mouse model, in vivo syngeneic transplant model\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — crystal structure + MD simulation + biophysical data + in vivo functional validation\",\n      \"pmids\": [\"31175292\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"STAT5B (not STAT5A) is the major STAT5 isoform driving BCR/ABL-induced leukemogenesis; STAT5B-deficient BCR/ABL+ cells show enhanced IFN-α and IFN-γ signatures, and IFN pathway inhibition rescues BCR/ABL+ colony formation of Stat5b-/- cells, demonstrating that STAT5B enables transformation by suppressing IFN responses.\",\n      \"method\": \"STAT5A/B-deficient BCR/ABL-expressing cells, RNA-seq, colony formation assays, IFN inhibition rescue experiments\",\n      \"journal\": \"Leukemia\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic KO + epistasis rescue + RNA-seq pathway analysis\",\n      \"pmids\": [\"30679796\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"STAT5B restrains human B-cell differentiation into plasmablasts via IL-21 signaling; STAT5B deletion in B cells diminishes IL-21-mediated SOCS3 induction and BCL6 repression, leading to enhanced plasmablast generation and class switching.\",\n      \"method\": \"CRISPR-mediated STAT5B deletion in B-cell lines, primary lymphocytes from STAT5B-null patients, RNA-seq, phospho-flow cytometry, in vitro differentiation assays\",\n      \"journal\": \"The Journal of allergy and clinical immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — CRISPR KO + human patient cells + multiple molecular and functional readouts\",\n      \"pmids\": [\"35469842\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"STAT5B is a latent transcription factor activated by JAK2-dependent tyrosine phosphorylation (at Y699) downstream of cytokine receptors (GH, IL-2, IL-15, prolactin, GM-CSF, EPO) and non-receptor tyrosine kinases (c-Src, BCR/ABL, EGFRvIII); upon phosphorylation it dimerizes, translocates to the nucleus (also constitutively shuttles as a monomer via a CRM1-dependent mechanism), binds GAS-element-containing promoters to drive target gene transcription (IGF-I, ALS, IGFBP-3, SOCS-2/3, CIS, Bcl-XL, cyclin D1), and is terminated by phosphotyrosine phosphatases and proteasome-dependent degradation; its transcriptional activity is further modulated by serine phosphorylation (Ser730, Ser193), bidirectional inhibitory cross-talk with PPARα/γ and HNF4α, inhibition of NFκB signaling by competition for p300/CBP, interaction with co-regulators such as CPEB3 and glucocorticoid receptor, and negative feedback through SOCS proteins; gain-of-function mutations (especially N642H in the SH2 domain) increase phospho-STAT5B persistence by enhancing pY-SH2 binding affinity and conferring dephosphorylation resistance, driving aggressive T/NK-cell lymphomas.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"STAT5B is a latent cytoplasmic transcription factor that is activated by JAK2-dependent tyrosine phosphorylation at Y699 downstream of cytokine receptors for growth hormone, prolactin, IL-2, IL-15, GM-CSF, and EPO, as well as by non-receptor tyrosine kinases including c-Src and BCR/ABL; upon phosphorylation it dimerizes, translocates to the nucleus, and binds GAS elements to drive transcription of target genes including IGF-I, ALS, IGFBP-3, Bcl-XL, SOCS-2, SOCS-3, and CIS [PMID:9231797, PMID:12682066, PMID:14761873, PMID:10428824]. Signal termination involves phosphotyrosine phosphatases and proteasome-dependent degradation, while transcriptional output is further tuned by serine phosphorylation at Ser730 and Ser193 (the latter regulated by mTOR and PP2A), bidirectional cross-talk with PPARα and HNF4α, competition with NF-κB for p300/CBP coactivators, and negative feedback through SOCS proteins [PMID:9892011, PMID:11731617, PMID:22442148, PMID:10514468, PMID:10628751]. STAT5B has non-redundant roles in NK cell cytolytic function, CD4+CD25high regulatory T cell homeostasis, GH-dependent sexually dimorphic liver gene expression, and restraint of B-cell plasmablast differentiation; germline loss-of-function mutations cause growth hormone insensitivity and immune dysregulation, while dominant-negative missense mutants dimerize with wild-type STAT5B to block its nuclear localization or DNA binding [PMID:9841920, PMID:16920911, PMID:10585399, PMID:35469842, PMID:29844444]. Somatic gain-of-function SH2-domain mutations, particularly N642H, increase pY699-SH2 binding affinity and confer dephosphorylation resistance, driving constitutive STAT5B activation in aggressive T-cell and NK-cell lymphomas [PMID:23596048, PMID:25586472, PMID:31175292].\",\n  \"teleology\": [\n    {\n      \"year\": 1996,\n      \"claim\": \"Establishing that STAT5A and STAT5B are phosphorylation-activated transcription factors that dimerize and bind DNA to drive differentiation-associated gene expression revealed STAT5B as a signal-dependent latent transcription factor.\",\n      \"evidence\": \"Isoform-specific antibodies, EMSA with supershift, transgenic mouse mammary tissue\",\n      \"pmids\": [\"8961260\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Upstream kinase not yet identified\", \"Individual contributions of STAT5A vs STAT5B not separated\"]\n    },\n    {\n      \"year\": 1997,\n      \"claim\": \"Demonstrating that JAK2 is required for GH-induced STAT5B tyrosine phosphorylation and that specific GH receptor cytoplasmic tyrosines are needed placed STAT5B directly downstream of the JAK2-GHR complex.\",\n      \"evidence\": \"GH receptor truncation/mutation constructs in COS and CHO cells, JAK2-deficient cell lines\",\n      \"pmids\": [\"9231797\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Precise STAT5B recruitment mechanism to receptor not defined\", \"Whether JAK2 directly phosphorylates Y699 or acts indirectly not resolved\"]\n    },\n    {\n      \"year\": 1998,\n      \"claim\": \"Knockout studies and isoform-specific biochemistry revealed non-redundant functions: STAT5B (not STAT5A) is essential for NK cell proliferation/cytolysis downstream of IL-2/IL-15, GM-CSF selectively activates STAT5B in neutrophils, and STAT5B binds GAS elements as homodimers with higher affinity than STAT5A, while only STAT5A forms tetramers.\",\n      \"evidence\": \"Stat5b−/− mice with NK cell assays; isoform-specific IP/EMSA in neutrophils; purified recombinant protein EMSA and COS-7 transfection\",\n      \"pmids\": [\"9841920\", \"9422769\", \"9742102\", \"9605930\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of isoform-specific receptor recruitment unknown\", \"Why STAT5B but not STAT5A is selectively activated in some cell types not mechanistically explained\"]\n    },\n    {\n      \"year\": 1999,\n      \"claim\": \"A suite of discoveries established how STAT5B signaling is terminated (phosphatases, proteasome, labile inhibitory factor), how continuous vs pulsatile GH patterns produce different STAT5B activation states (explaining sexual dimorphism of liver gene expression), and how c-Src activates STAT5B via a JAK2-independent mechanism that is functionally distinct from cytokine-driven activation.\",\n      \"evidence\": \"Pharmacological dissection (MG132, pervanadate, cycloheximide, H7) in liver cells; Stat5b−/− mice with pulsatile GH replacement; dominant-negative JAK2 + immunofluorescence in transfected cells\",\n      \"pmids\": [\"9892011\", \"9973252\", \"10585399\", \"10428824\", \"10630411\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Identity of the labile protein factor required for signaling termination not determined\", \"How Src-phosphorylated nuclear STAT5B fails to activate certain promoters remains unclear\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"Showing that STAT5B inhibits NF-κB signaling by competing for limiting p300/CBP coactivators revealed a transcription-independent function of activated STAT5B as a coactivator titrator, broadening its role beyond direct DNA binding.\",\n      \"evidence\": \"PRL-stimulated reporter assays with p300/CBP rescue, dominant-negative STAT5B, C-terminal deletion mutants\",\n      \"pmids\": [\"10628751\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether this occurs on endogenous NF-κB target genes in vivo not shown\", \"Stoichiometry of STAT5B vs NF-κB competition for p300/CBP not quantified\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Identification of Tyr-699 as the essential activating phosphosite plus three additional EGF-induced tyrosine sites (725, 740, 743) that negatively modulate transcription, and of Ser730 as a promoter-context-dependent modulator of transcriptional output, revealed multi-site phosphorylation-based regulation of STAT5B activity.\",\n      \"evidence\": \"Mass spectrometry + site-directed mutagenesis + reporter assays in EGFR-overexpressing HEK293 and GH-stimulated cells\",\n      \"pmids\": [\"11751923\", \"11731617\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Kinase(s) responsible for Y725/740/743 phosphorylation not identified\", \"In vivo relevance of Ser730 phosphorylation not tested\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Discovery that STAT5B constitutively shuttles between nucleus and cytoplasm via a CRM1-dependent export pathway independently of cytokine stimulation, with a separate dimerization-dependent import mechanism upon activation, defined two distinct nuclear trafficking modes.\",\n      \"evidence\": \"Leptomycin B treatment, Y699 dimerization-defective mutant, coiled-coil domain deletions, immunofluorescence in Ba/F3 cells\",\n      \"pmids\": [\"11971004\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Nuclear import receptor for the monomer pathway not identified\", \"Functional consequence of constitutive shuttling remains unclear\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"In vivo adenoviral gene transfer demonstrated that STAT5B is necessary and sufficient for GH-stimulated transcription of the IGF-I, ALS, IGFBP-3, SOCS-1, SOCS-2, and CIS genes in liver, establishing it as the master mediator of the hepatic GH-IGF axis.\",\n      \"evidence\": \"Dominant-negative and constitutively active STAT5B adenoviral vectors delivered to pituitary-deficient rats, with multi-gene expression readouts\",\n      \"pmids\": [\"12682066\", \"14761873\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Chromatin-level mechanism of target gene selectivity not determined at this stage\", \"Contribution of STAT5A to residual GH responses in liver not fully excluded\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"ChIP identification of two distinct STAT5B-occupied GH response elements in the IGF-I locus, each with paired high- and low-affinity sites, provided the first chromatin-level map of STAT5B binding at a key physiological target.\",\n      \"evidence\": \"Chromatin immunoprecipitation in rat liver, quantitative binding studies, reconstitution reporter assays\",\n      \"pmids\": [\"16339156\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether STAT5B tetramers vs dimers occupy these paired sites in vivo not resolved\", \"Enhancer-promoter looping mechanism not addressed\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Multiple studies expanded STAT5B's biological reach: it is required for CD4+CD25high Treg cell accumulation and FOXP3 expression (shown by a human A630P loss-of-function mutation), cooperates with nuclear EGFRvIII on the Bcl-XL promoter in glioblastoma, and mediates thrombin-induced VSMC growth via STAT3 co-association.\",\n      \"evidence\": \"Patient germline mutation with Treg functional assays; nuclear Co-IP + ChIP + shRNA in glioblastoma cells; dominant-negative STAT5B adenovirus + Co-IP in VSMC\",\n      \"pmids\": [\"16920911\", \"22729867\", \"16527988\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether STAT5B directly binds FOXP3 regulatory elements not tested\", \"How EGFRvIII translocates to the nucleus to partner with STAT5B not explained\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Identification of Ser-193 as an mTOR-dependent, PP2A-reversed cytoplasmic phosphorylation event required for maximal STAT5B transcriptional activity revealed an additional signaling input that modulates STAT5B before nuclear entry.\",\n      \"evidence\": \"Mass spectrometry, phospho-specific antibodies, mTOR/PP2A inhibitors, site-directed mutagenesis, HEK293 reconstitution\",\n      \"pmids\": [\"22442148\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether mTOR directly phosphorylates Ser-193 or acts through an intermediate kinase not determined\", \"Interplay between Ser-193 and Ser-730 phosphorylation not studied\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Discovery of somatic gain-of-function STAT5B mutations (N642H, Y665F) in the SH2 domain in LGL leukemia established STAT5B as a directly mutated oncogene in human cancer.\",\n      \"evidence\": \"Exome/transcriptome sequencing of LGL leukemia, targeted amplicon sequencing, transfection of mutant constructs with phosphorylation and transcriptional activity assays\",\n      \"pmids\": [\"23596048\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism by which N642H increases phosphorylation persistence not yet biophysically explained\", \"Frequency and spectrum of STAT5B mutations across other lymphoid malignancies not yet surveyed\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Biophysical characterization showed that N642H creates enhanced pY699-SH2 binding affinity (SPR) and dephosphorylation resistance, explaining the prolonged phospho-STAT5B persistence observed in N642H-driven lymphomas and providing a structural rationale for oncogenicity.\",\n      \"evidence\": \"Surface plasmon resonance, molecular modelling, transduction of NK and γδ-T cells, JAK1/2 inhibitor treatment\",\n      \"pmids\": [\"25586472\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Crystal structure of mutant not yet available at this time\", \"Whether dephosphorylation resistance reflects altered phosphatase binding or intrinsic dimer stability not distinguished\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Functional dissection of dominant-negative STAT5B germline mutations showed that distinct mutants fail at different steps (nuclear localization vs DNA binding) yet all retain dimerization capacity, establishing the molecular logic of dominant-negative STAT5B disease.\",\n      \"evidence\": \"Patient germline mutations, nuclear localization assays, EMSA, dimerization assays, reporter assays\",\n      \"pmids\": [\"29844444\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether heterodimers with STAT5A are also formed and functionally impaired not tested\", \"In vivo rescue of dominant-negative phenotype not demonstrated\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Crystal structures of wild-type STAT5B and the N642H mutant revealed alternative SH2 domain conformations and dephosphorylation resistance at the structural level, while functional studies showed STAT5B (not STAT5A) is the major driver of BCR/ABL leukemogenesis by suppressing interferon responses.\",\n      \"evidence\": \"X-ray crystallography + MD simulations + transgenic/syngeneic mouse models; Stat5b−/− BCR/ABL+ cells + RNA-seq + IFN inhibition rescue\",\n      \"pmids\": [\"31175292\", \"30679796\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Full-length phosphorylated dimer structure not yet solved\", \"How STAT5B suppresses IFN pathway transcription at the chromatin level not defined\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"CRISPR deletion and patient-derived cells showed STAT5B restrains B-cell differentiation into plasmablasts via IL-21-mediated SOCS3 induction and BCL6 repression, expanding STAT5B's non-redundant immune roles to humoral immunity.\",\n      \"evidence\": \"CRISPR KO in B-cell lines, primary cells from STAT5B-null patients, RNA-seq, phospho-flow, in vitro differentiation\",\n      \"pmids\": [\"35469842\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct STAT5B binding at SOCS3 and BCL6 loci in B cells not shown by ChIP\", \"Whether enhanced plasmablast formation contributes to autoimmunity in STAT5B-deficient patients not established\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Key unresolved questions include: the full-length phosphorylated STAT5B dimer structure, the identity of nuclear import receptors for monomeric STAT5B, the chromatin-level basis for promoter selectivity among STAT5B target genes, and the therapeutic window for selective STAT5B inhibition in N642H-driven lymphomas.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Full-length activated dimer crystal structure not available\", \"Nuclear import receptor for constitutive monomer shuttling not identified\", \"Genome-wide chromatin occupancy comparison of STAT5B vs STAT5A not performed in most cell types\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0003677\", \"supporting_discovery_ids\": [0, 3, 5, 24]},\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [0, 5, 19, 22, 28, 43]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [18, 33]},\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [8, 18, 28, 30]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [1, 4, 6, 9, 11, 15, 17, 37]},\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [0, 5, 19, 22, 24, 28, 43]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [2, 25, 42, 43]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [34, 35, 41, 42]}\n    ],\n    \"complexes\": [\n      \"STAT5B homodimer\",\n      \"STAT5A/STAT5B heterodimer\",\n      \"EGFRvIII-STAT5B nuclear complex\"\n    ],\n    \"partners\": [\n      \"JAK2\",\n      \"STAT5A\",\n      \"STAT3\",\n      \"GHR\",\n      \"CPEB3\",\n      \"EGFRvIII\",\n      \"SRC\",\n      \"BCR-ABL\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}